

Prof. İBRAHİM CELALETTİN HAZNEDAROĞLU

Personal Information

Email: icelalettin.haznedaroglu@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/i.celalettin.haznedaroglu>

International Researcher IDs

ORCID: 0000-0001-8028-9462

Publons / Web Of Science ResearcherID: B-7408-2009

ScopusID: 35459001500

Yoksis Researcher ID: 170575

Education Information

Post Doctorate, Hacettepe University, Tıp Fakültesi, Turkey 1989 - Continues

Expertise In Medicine, Hacettepe University, Tıp Fakültesi, Turkey 1989 - 1993

Foreign Languages

English, C1 Advanced

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Hematology

Academic Titles / Tasks

Professor, Hacettepe University, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2012 - 2016

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid Leukemia**
Kronik Miyeloid Lösemi Tanılı Hastada Nilotinib ile İlişkili Çoklu Sessiz Arteriyel Darlık
Tokatlı M., Ismayilov R., ÇINAR O. E., HAZNEDAROĞLU İ. C.
Turkish Journal of Hematology, vol.41, no.1, pp.59-60, 2024 (SCI-Expanded)
- II. **Enterotoxins A and B produced by Staphylococcus aureus increase cell proliferation, invasion and cytarabine resistance in acute myeloid leukemia cell lines.**
TÜRK S., Yanpar H., Baesmat A. S., Canli S., ÇINAR O. E., MALKAN Ü. Y., TÜRK C., HAZNEDAROĞLU İ. C., UÇAR G.
Heliyon, vol.9, no.9, 2023 (SCI-Expanded)
- III. **The effects of Ankaferd hemostat on preventing oral mucositis in colorectal cancer patients receiving chemotherapy**
Karacan Y., YILDIZ H., EVRENSEL T., HAZNEDAROĞLU İ. C.
Supportive Care in Cancer, vol.31, no.7, 2023 (SCI-Expanded)
- IV. **Harbinger of Trouble; Fingerprints in the Pre-Senile Stage of NK Cell's Dysfunction**

TÜRK S., Baesmat A. S., YILMAZ A., MALKAN Ü. Y., TÜRK C., HAZNEDAROĞLU İ. C., UÇAR G.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.33, no.2, pp.66-74, 2023 (SCI-Expanded)

- V. **Pathobiological alterations affecting the distinct clinical courses of pediatric versus adult COVID-19 syndrome**
ŞENEL E., TÜRK S., MALKAN Ü. Y., Peker M. Ç., TÜRK C., GÜNER H. R., UÇAR G., İZDEŞ S., KAYAASLAN B., BAYHAN G. İ., et al.
Turkish Journal of Medical Sciences, vol.53, no.5, pp.1194-1204, 2023 (SCI-Expanded)
- VI. **A single-center experience of haploidentical stem cell transplantation in hematological malignancies**
MALKAN Ü. Y., GÖKER H., DEMİROĞLU H., Tekin F., Akdemir B., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.
Turkish Journal of Medical Sciences, vol.53, no.1, pp.352-359, 2023 (SCI-Expanded)
- VII. **Effectiveness of Mesenchymal Stem Cell Therapy for COVID-19 Patients in the Intensive Care Unit: A Case-Control Study**
Canbaz H., İdiz U. O., Cankar Dal H., Kaçıroğlu F., Taş S., Çubukçu H. C., Beştemir A., Gülşen M., Polat İ. T., Laloğlu A., et al.
Turkish journal of haematology : official journal of Turkish Society of Haematology, vol.39, no.4, pp.222-229, 2022 (SCI-Expanded)
- VIII. **Comment on Zamfir et al. Hematologic Malignancies Diagnosed in the Context of the mRNA COVID-19 Vaccination Campaign: A Report of Two Cases. Medicina 2022, 58, 874**
ÇINAR O. E., Erdogdu B., KARADENİZ M., ÜNAL S., MALKAN Ü. Y., GÖKER H., HAZNEDAROĞLU İ. C.
MEDICINA-LITHUANIA, vol.58, no.11, 2022 (SCI-Expanded)
- IX. **NK-cell dysfunction of acute myeloid leukemia in relation to the renin-angiotensin system and neurotransmitter genes**
TÜRK S., Baesmat A. S., YILMAZ A., TÜRK C., MALKAN Ü. Y., UÇAR G., HAZNEDAROĞLU İ. C.
OPEN MEDICINE, vol.17, no.1, pp.1495-1506, 2022 (SCI-Expanded)
- X. **Review on Characteristics and Analytical Methods of Rivaroxaban**
REÇBER T., HAZNEDAROĞLU İ. C., ÇELEBİER M.
CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, vol.52, no.4, pp.865-877, 2022 (SCI-Expanded)
- XI. **Efficacy of eltrombopag in thrombocytopenia after hematopoietic stem cell transplantation**
KARATAŞ A., GÖKER H., DEMİROĞLU H., MALKAN Ü. Y., Velet M., ÇINAR O. E., Erdogdu B., KARADENİZ M., SAYINALP N., AKSU S., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.2, pp.413-419, 2022 (SCI-Expanded)
- XII. **Covid-19 Related Fatality and Risk Factors in Multiple Myeloma: A Multicenter Cohort Study**
KARADENİZ M., GÖKER H., Aydın O., Turgut M., MALKAN Ü. Y., Sener E., Erdogdu B., ÇINAR O. E., HAZNEDAROĞLU İ. C., SAYINALP N., et al.
UHOD - Uluslararası Hematoloji-Onkoloji Dergisi, vol.32, no.4, pp.209-213, 2022 (SCI-Expanded)
- XIII. **Hematopoietic Adverse Events Associated with BNT162b2 mRNA Covid-19 Vaccine**
Erdogdu B., ÇINAR O. E., Malkan Ü. Y., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.32, no.1, pp.65-67, 2022 (SCI-Expanded)
- XIV. **Bone Marrow Origin of Coronary Artery Diseases: The Impact of the Local Renin-Angiotensin System**
KARAKULAK U. N., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.
ACTA CARDIOLOGICA SINICA, vol.38, no.1, pp.13-20, 2022 (SCI-Expanded)
- XV. **Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia**
İLHAN O., Narli Ozdemir Z., DALVA K., ARSLAN A., Okay Ozgeyik M., Ipek S., SAYDAM G., HAZNEDAROĞLU İ. C.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol.43, no.5, pp.1110-1116, 2021 (SCI-Expanded)
- XVI. **Long-term results of allogeneic peripheral blood hematopoietic stem cell transplantation for severe aplastic anemia**
ALADAĞ KARAKULAK E., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.

TRANSFUSION AND APHERESIS SCIENCE, vol.60, no.2, 2021 (SCI-Expanded)

- XVII. **Allogeneic Hematopoietic Stem-Cell Transplantation Improves Disease-Free Survival Compared to Pediatric-Inspired Berlin-Frankfurt-Munster Chemotherapy in Adult Acute Lymphoblastic Leukemia**
ALADAĞ KARAKULAK E., Aktimur S. H., Aydin O., DEMİROĞLU H., BÜYÜKAŞIK Y., AKSU S., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., SAYINALP N., Turgut M., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.21, no.3, pp.147-153, 2021 (SCI-Expanded)
- XVIII. **Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors**
KARAKULAK U. N., ALADAĞ KARAKULAK E., HEKİMSOY V., ŞAHİNER M. L., KAYA E. B., ÖZER N., AKSU S., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., et al.
CARDIOVASCULAR TOXICOLOGY, vol.21, no.3, pp.216-223, 2021 (SCI-Expanded)
- XIX. **Evaluation of Prognostic Significance of the International Staging System According to Glomerular Filtration Rate in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation**
Ciftçiler R., GÖKER H., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., ÖZCEBE O., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF HEMATOLOGY, vol.38, no.1, pp.33-40, 2021 (SCI-Expanded)
- XX. **Covid-19 scientific publications from Turkey**
Ciftçiler R., HAZNEDAROĞLU İ. C., TUFAN A., ÖZTÜRK M. A.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.3, pp.877-889, 2021 (SCI-Expanded)
- XXI. **Could Targeting HMGB1 be Useful for the Clinical Management of COVID-19 Infection?**
ÇELEBİER M., HAZNEDAROĞLU İ. C.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, vol.24, no.4, pp.587-590, 2021 (SCI-Expanded)
- XXII. **Interferon-Gene Family Alterations Following the SARS-Cov Infection in Association with Iron Metabolism and Lymphoid Biology**
Malkan Ü. Y., TÜRK S., Turk C., Temirci E. S., Koker I., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.2, pp.67-78, 2021 (SCI-Expanded)
- XXIII. **Efficacy and safety of ruxolitinib in patients with myelofibrosis: a retrospective and multicenter experience in Turkey**
SOYER N., ALİ R., Turgut M., HAZNEDAROĞLU İ. C., Yılmaz F., AYDOĞDU İ., PİR A., Karakus V., ÖZGÜR G., KİS C., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.3, pp.1033-1042, 2021 (SCI-Expanded)
- XXIV. **Protein Kinases in Hematological Disorders**
OKAY M., HAZNEDAROĞLU İ. C.
PROTEIN KINASE-MEDIATED DECISIONS BETWEEN LIFE AND DEATH, vol.1275, pp.383-393, 2021 (SCI-Expanded)
- XXV. **Current community transmission and future perspectives on the COVID-19 process**
TÜRK S., Turk C., Malkan Ü. Y., Temirci E. S., Peker M. C., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.3, pp.1001-1011, 2021 (SCI-Expanded)
- XXVI. **Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content**
BEYAZIT F., BEYAZIT Y., Tanoglu A., HAZNEDAROĞLU İ. C.
MEDICAL HYPOTHESES, vol.143, 2020 (SCI-Expanded)
- XXVII. **Pathobiological Interactions of Local Bone Marrow Renin-Angiotensin System and Central Nervous System in Systemic Arterial Hypertension**
Ciftçiler R., HAZNEDAROĞLU İ. C.
FRONTIERS IN ENDOCRINOLOGY, vol.11, 2020 (SCI-Expanded)
- XXVIII. **Spontaneous subepithelial hemorrhage of renal pelvis and ureter (Antopol-Goldman lesion) in hemophilia A patient with inhibitor Case report and review of the literature**
ŞAHİN T. K., ALADAĞ KARAKULAK E., Setterzade E., SAİN GÜVEN G., HAZNEDAROĞLU İ. C., AKSU S.
MEDICINE, vol.99, no.26, 2020 (SCI-Expanded)
- XXIX. **In vitro analysis of the renin-angiotensin system and inflammatory gene transcripts in human bronchial epithelial cells after infection with severe acute respiratory syndrome coronavirus**

- Turk C., TÜRK S., Temirci E. S., Malkan Ü. Y., HAZNEDAROĞLU İ. C.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.21, no.2, 2020 (SCI-Expanded)
- XXX. **Richter's transformation in patients with chronic lymphocytic leukemia: a cohort study about risk factors**
OKAY M., GÜNEŞ G., Malkan Ü. Y., Heziyev T., GÖKER H., HAZNEDAROĞLU İ. C., Ozcebe O., SAYINALP N.
LEUKEMIA & LYMPHOMA, vol.61, pp.50-52, 2020 (SCI-Expanded)
- XXXI. **WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors**
HAZNEDAROĞLU İ. C., KUZU I., İLHAN O.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.1, pp.42-47, 2020 (SCI-Expanded)
- XXXII. **COVID-19, Renin-Angiotensin System, and Hematopoiesis**
Ciftçiler R., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.3, pp.207-208, 2020 (SCI-Expanded)
- XXXIII. **The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia**
Ciftçiler R., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., AKSU S., DEMİROĞLU H., GÖKER H., Malkan Ü. Y., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.2, pp.116-120, 2020 (SCI-Expanded)
- XXXIV. **Ankaferd Hemostat Affects Etoposide Resistance of the Malignant Melanoma Cells**
Ghasemi M., OKAY M., Malkan Ü. Y., TÜRK S., Jabbar J., Hocaoglu H., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.1, pp.43-53, 2020 (SCI-Expanded)
- XXXV. **The comparison of bone marrow kinetics between patients with acute myeloid leukemia and acute promyelocytic leukemia after induction chemotherapy**
Ciftçiler R., HAZNEDAROĞLU İ. C., Ozcebe O., AKSU S., SAYINALP N., GÖKER H., DEMİROĞLU H., BÜYÜKAŞIK Y.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, vol.42, no.1, pp.17-21, 2020 (SCI-Expanded)
- XXXVI. **Local Bone Marrow Renin-Angiotensin System and COVID-19**
Ciftçiler R., Ciftçiler A. E., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.113-120, 2020 (SCI-Expanded)
- XXXVII. **Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat**
HAZNEDAROĞLU İ. C., ÇELEBİER M.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.50, no.5, pp.1434-1435, 2020 (SCI-Expanded)
- XXXVIII. **Evaluation of the Survival Outcomes of Multiple Myeloma Patients According to Their Plasmacytoma Presentation at Diagnosis**
Ciftçiler R., GÖKER H., DEMİROĞLU H., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., Malkan Ü. Y., BÜYÜKAŞIK Y., Ozcebe O.
TURKISH JOURNAL OF HEMATOLOGY, vol.37, no.4, pp.256-262, 2020 (SCI-Expanded)
- XXXIX. **Impact of Time Between Induction Chemotherapy and Complete Remission on Survival Outcomes in Patients With Acute Myeloid Leukemia**
Ciftçiler R., DEMİROĞLU H., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., Ozcebe O., GÖKER H., Aydın M. S., BÜYÜKAŞIK Y.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.11, pp.729-734, 2019 (SCI-Expanded)
- XL. **A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia**
Ciftçiler R., Sağlam E. A., Inanc A., Ozcebe O., HAZNEDAROĞLU İ. C.
CANCER GENETICS, vol.237, pp.78-81, 2019 (SCI-Expanded)
- XLI. **Ghosal hematodiaphyseal dysplasia with autoimmune anemia in two adult siblings**
Ciftçiler R., BÜYÜKAŞIK Y., Sağlam E. A., HAZNEDAROĞLU İ. C.
TRANSFUSION AND APHERESIS SCIENCE, vol.58, no.4, pp.449-452, 2019 (SCI-Expanded)
- XLII. **The impact of At1r inhibition via losartan on the anti-leukaemic effects of doxorubicin in acute myeloid leukaemia**
Ghasemi M., OKAY M., TÜRK S., Naeemae R., Guver E., Malkan Ü. Y., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.20, no.2, 2019 (SCI-Expanded)

- XLIII. The Impact of AT1R Inhibition via Losartan on the Anti-Leukemic Effects of Doxorubicin in Acute Myeloid Leukemia.**
GHASEMİ m., OKAY M., TÜRK S., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., MALKAN Ü. Y.
Journal Of The Renin-Angiotensin-Aldosterone System, 2019 (SCI-Expanded)
- XLIV. The impact of JAK/STAT inhibitor ruxolutinib on the genesis of lymphoproliferative diseases**
TÜRK TÜRK S., HAZNEDAROĞLU İ. C., TÜRK C.
Turkish Journal Of Medical Sciences, 2019 (SCI-Expanded)
- XLV. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia**
Ciftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., Malkan Ü. Y., GÖKER H.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol.19, no.3, pp.177-182, 2019 (SCI-Expanded)
- XLVI. Fibrosis Development, Leukemic Transformation and Secondary Malignancies Complicating the Clinical Course of Essential Thrombocythemia**
Ciftciler R., AKSU S., Malkan Ü. Y., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.29, no.1, pp.14-21, 2019 (SCI-Expanded)
- XLVII. Indications and outcomes of splenectomy for hematological disorders**
Ciftciler R., Pasayeva A., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C.
OPEN MEDICINE, vol.14, no.1, pp.491-496, 2019 (SCI-Expanded)
- XLVIII. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency**
ALADAĞ KARAKULAK E., AKSU S., DEMİROĞLU H., SAYINALP N., GÖKER H., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.5, pp.1560-1563, 2019 (SCI-Expanded)
- XLIX. Effects of Ankaferd Hemostat on Helicobacter pylori strains and antibiotic resistance**
Ciftciler R., KOLUMAN A., HAZNEDAROĞLU İ. C., Akar N.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.1, pp.347-355, 2019 (SCI-Expanded)
- L. Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., Malkan Ü. Y., Ciftciler R., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.4, pp.985-992, 2019 (SCI-Expanded)
- LI. Branch retinal vein occlusion associated with platelet activation**
Beyazyildiz E., Citirik M., Simsek M., Beyazyildiz O., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.1, pp.283-287, 2019 (SCI-Expanded)
- LII. The impact of JAK/STAT inhibitor ruxolitinib on the genesis of lymphoproliferative diseases**
Turk C., OKAY M., TÜRK S., Temirci E. S., Javad O., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.2, pp.661-674, 2019 (SCI-Expanded)
- LIII. Current perspectives for the treatment of chronic myeloid leukemia**
ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.1, pp.1-10, 2019 (SCI-Expanded)
- LIV. Discontinuation of imatinib mesylate could improve renal impairment in chronic myeloid leukemia**
Malkan U. Y., HAZNEDAROĞLU İ. C.
OPEN MEDICINE, vol.14, no.1, pp.22-24, 2019 (SCI-Expanded)
- LV. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study**
Ciftciler R., GÖKER H., DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., Ozcebe O., Tekin F., BÜYÜKAŞIK Y.
TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.2, pp.88-96, 2019 (SCI-Expanded)
- LVI. Tumor Lysis Syndrome Due to Targeting of Hepatocellular Carcinoma Associated with Chronic Myelomonocytic Leukemia**

- OKAY M., ÇETİK S., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.36, no.3, pp.218-219, 2019 (SCI-Expanded)
- LVII. **The factors affecting early death in newly diagnosed APL patients**
Ciftciler R., HAZNEDAROĞLU İ. C., AKSU S., Ozcebe O., SAYINALP N., Malkan Ü. Y., BÜYÜKAŞIK Y.
OPEN MEDICINE, vol.14, no.1, pp.647-652, 2019 (SCI-Expanded)
- LVIII. **Analysis of the Antiproliferative Effect of Ankaferd Hemostat on Caco-2 Colon Cancer Cells via LC/MS Shotgun Proteomics Approach**
KOÇAK E., ÇELEBİER M., HAZNEDAROĞLU İ. C., ALTINÖZ S.
BIOMED RESEARCH INTERNATIONAL, vol.2019, 2019 (SCI-Expanded)
- LIX. **The Antithrombin Effect of Ankaferd Hemostat (ABS) Is Related to the High Iron Content of the Medicine**
OKAY M., Ozturk Y., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.25, 2019 (SCI-Expanded)
- LX. **Effect of postremission high dose cytarabine-based consolidation chemotherapy before allogenic stem cell transplantation in outcomes of acute myeloid leukemia patients**
CIFTCILER R., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., AKSU S., Sayinalp N., MALKAN Ü. Y., HAZNEDAROĞLU İ. C., Ozcebe O., GÖKER H.
TRANSFUSION AND APHERESIS SCIENCE, vol.57, no.6, pp.752-755, 2018 (SCI-Expanded)
- LXI. **On Being a "Physician Patient" with His Own Experimental Therapeutic Drug**
Ciftciler R., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.35, no.4, pp.302-303, 2018 (SCI-Expanded)
- LXII. **Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up**
SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., AKAY O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
HEMATOLOGY, vol.23, no.10, pp.771-777, 2018 (SCI-Expanded)
- LXIII. **Pediatric Chemotherapeutic Regimen (BFM-95) is Superior for Overall Survival in Adult Acute Lymphoblastic Leukemia**
KARCIOĞLU A. M., OKAY M., BÜYÜKAŞIK Y., Malkan Ü. Y., SAYINALP N., DEMİROĞLU H., GÖKER H., AKSU S., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.28, no.4, pp.254-260, 2018 (SCI-Expanded)
- LXIV. **The impact of chemo/immune therapy-related cytopenias on the clinical course of chronic lymphoid leukemia**
Malkan Ü. Y., OKAY M., HAZNEDAROĞLU İ. C., GÜNEŞ G., Aslan N. A., ÖZCEBE O. İ., AKSU S., BÜYÜKAŞIK Y., DEMİROĞLU H., SAYINALP N.
LEUKEMIA & LYMPHOMA, vol.58, pp.96, 2017 (SCI-Expanded)
- LXV. **Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases**
Koluman A., Akar N., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.93-98, 2017 (SCI-Expanded)
- LXVI. **Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms**
SOYER N., HAZNEDAROĞLU İ. C., Comert M., Cekdemir D., YILMAZ M., ÜNAL A., Cagliyan G., Bilgir O., İLHAN O., Ozdemirkiran F., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.27-33, 2017 (SCI-Expanded)
- LXVII. **Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission**
AYDIN M. S., BOZKURT S., GÜNEŞ G., Malkan Ü. Y., Aslan T., ETGÜL S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., GÖKER H., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.34, no.1, pp.103-104, 2017 (SCI-Expanded)
- LXVIII. **A myelofibrosis case that develops mycobacterial infection after ruxolitinib treatment**
Malkan Ü. Y., HAZNEDAROĞLU İ. C.

- INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.10, no.4, pp.7304-7307, 2017 (SCI-Expanded)
- LXIX. **Ankaferd hemostat induces DNA damage, apoptosis and cytotoxic activity by generating reactive oxygen species in melanoma and normal cell lines**
KOÇYİĞİT A., GÜLER E. M., HAZNEDAROĞLU İ. C., Malkan Ü. Y.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.10, no.2, pp.2116-2126, 2017 (SCI-Expanded)
- LXX. **Lipotoxicity-Related Hematological Disorders in Obesity**
HAZNEDAROĞLU İ. C., MALKAN Ü. Y.
OBESITY AND LIPOTOXICITY, vol.960, pp.469-487, 2017 (SCI-Expanded)
- LXXI. **Clinical associations, biological risk factors and outcomes of cerebral venous sinus thrombosis**
Gunes H. N., Cokal B. G., Guler S. K., Yoldas T. K., Malkan Ü. Y., Demircan C. S., YÖN M. İ., Yoldas Z., GÜNEŞ G., HAZNEDAROĞLU İ. C.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.44, no.6, pp.1454-1461, 2016 (SCI-Expanded)
- LXXII. **Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase**
SAYDAM G., HAZNEDAROĞLU İ. C., KAYNAR L., Yavuz A., ALİ R., GÜVENÇ B., AKAY O. M., Baslar Z., ÖZBEK U., SÖNMEZ M., et al.
EXPERT OPINION ON PHARMACOTHERAPY, vol.17, no.14, pp.1851-1858, 2016 (SCI-Expanded)
- LXXIII. **Splenic artery embolization with Ankaferd blood stopper in a sheep model**
KOÇ O., Acar K., Ozbek O., Guler I., Saritas K., Erdem T. B., Solak Y., Toy H., Kucukapan A., Ozbek S., et al.
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, vol.22, no.4, pp.354-357, 2016 (SCI-Expanded)
- LXXIV. **Reply: Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib**
Malkan U. Y., GÜNEŞ G., ETGÜL S., Aslan T., Aydin S., HAZNEDAROĞLU İ. C.
ANNALS OF PHARMACOTHERAPY, vol.50, no.4, pp.336, 2016 (SCI-Expanded)
- LXXV. **Idelalisib at the Crossroads of B-Cell Lymphoproliferative Disorders**
AKSU S., Ayyıldız O., ETGÜL S., GÖKER H., GÜNEŞ G., HAZNEDAROĞLU İ. C., İLHAN O., Kaynar L. G., Malkan U. Y., ÖZDEMİR E., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.12-19, 2016 (SCI-Expanded)
- LXXVI. **Molecular Management of Chronic Lymphocytic Leukemia: Towards a Chemotherapy-Free Approach**
SAYINALP N., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.1-11, 2016 (SCI-Expanded)
- LXXVII. **Peripheral FLT-3 ligand levels as a pathobiological parameter during the clinical course of acute myeloid leukemia**
Sahin M., HAZNEDAROĞLU İ. C., Ozbalci D.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.46, no.6, pp.1889-1893, 2016 (SCI-Expanded)
- LXXVIII. **The Impact of Iron Overload on Transplant-Related Complications and Prognosis of Acute Leukemias**
Malkan U. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., Yayar O., ETGÜL S., Aslan T., Aydin S., GÖKER H., DEMİROĞLU H., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.54-60, 2016 (SCI-Expanded)
- LXXIX. **A CML case with resistant pleural effusion with tyrosine kinase inhibitor treatment**
Malkan Ü. Y., HAZNEDAROĞLU İ. C.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.9, no.7, pp.14884-14887, 2016 (SCI-Expanded)
- LXXX. **Expression Profiles of the Individual Genes Corresponding to the Genes Generated by Cytotoxicity Experiments with Bortezomib in Multiple Myeloma**
GHASEMİ m., ALPSOY S., TÜRK TÜRK S., MALKAN Ü. Y., ATAKAN Ş., HAZNEDAROĞLU İ. C., GÜNEŞ G., Gunduz M., Yilmaz B., Etgul S., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.4, pp.286-292, 2016 (SCI-Expanded)
- LXXXI. **The Prognosis of Adult Burkitt's Cell Leukemia in Real-Life Clinical Practice**

Malkan Ü. Y., GÜNEŞ G., GÖKER H., HAZNEDAROĞLU İ. C., Acar K., ELİAÇIK E., ETGÜL S., Aslan T., Balaban S., DEMİROĞLU H., et al.

TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.4, pp.281-285, 2016 (SCI-Expanded)

LXXXII. A Bing-Neel syndrome case

Malkan Ü. Y., HAZNEDAROĞLU İ. C.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.9, no.11, pp.22660-22663, 2016 (SCI-Expanded)

LXXXIII. The Impact of Jak1/Jak2 Inhibitor Ruxolitinib on the Spleen Size and Symptom Burden in Myeloproliferative Diseases

Aktimur S. H., Malkan U. Y., Eyupoglu D. N., HAZNEDAROĞLU İ. C., KELKİTLİ E., Atay H. M., GÜNEŞ G., ETGÜL S., Aslan T., GÖKER H., et al.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.153-158, 2016 (SCI-Expanded)

LXXXIV. Dasatinib-Induced Severe Hemorrhagic Colitis in Chronic Myeloid Leukemia

Kekilli M., Tanoglu A., Cakar M. K., Guney G., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.1, pp.67-68, 2016 (SCI-Expanded)

LXXXV. Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

BEKTAŞ Ö., ÜNER A., ELİAÇIK E., Uz B., Isik A., ETGÜL S., BOZKURT S., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., et al.

TURKISH JOURNAL OF HEMATOLOGY, vol.33, no.2, pp.119-126, 2016 (SCI-Expanded)

LXXXVI. Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids

Koluman A., Akar N., Malkan U. Y., HAZNEDAROĞLU İ. C.

BIOMED RESEARCH INTERNATIONAL, vol.2016, 2016 (SCI-Expanded)

LXXXVII. Bone marrow fibrosis may be an effective independent predictor of the 'TKI drug response level' in chronic myeloid leukemia

ELİAÇIK E., Isik A., Aydin C., ÜNER A., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., Ozcebe O., et al.

HEMATOLOGY, vol.20, no.7, pp.392-396, 2015 (SCI-Expanded)

LXXXVIII. High frequency of autonomous T-cell proliferation compatible with T-cell large granular lymphocytic leukemia in patients with cytopenia of unknown etiology

BEKTAŞ Ö., ÜNER A., Aydin S. M., ELİAÇIK E., Uz B., Isik A., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., AKSU S., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.102, no.2, pp.211-217, 2015 (SCI-Expanded)

LXXXIX. Management of De Novo CML and Imatinib-Induced Acute Rhabdomyolysis With the Second-Generation TKI, Dasatinib

Malkan Ü. Y., GÜNEŞ G., ETGÜL S., Aslan T., Balaban S., HAZNEDAROĞLU İ. C.

ANNALS OF PHARMACOTHERAPY, vol.49, no.6, pp.740-742, 2015 (SCI-Expanded)

XC. In Vivo Healing Effects of Ankaferd Blood Stopper on the Residual Pancreatic Tissue in a Swine Model of Distal Pancreatectomy

Karaman K., Bostanci E. B., Celep B., Dincer N., Kurt M., Teke Z., Akoglu M., BİLGİLİ H., Uluhan S., HAZNEDAROĞLU İ. C.

INDIAN JOURNAL OF SURGERY, vol.77, no.3, pp.176-181, 2015 (SCI-Expanded)

XCI. Severe radiation esophagitis successfully treated with Ankaferd hemostat

ÖZTÜRK Ö., KÖKLÜ S., BAŞAR Ö., HAZNEDAROĞLU İ. C.

GASTROINTESTINAL ENDOSCOPY, vol.81, no.4, pp.1048-1049, 2015 (SCI-Expanded)

XCII. High iron content of Ankaferd hemostat as a clue for its hemostatic action of red blood cell origin

Akar N., Ardicoglu Y., ÖKTEM Z., ERDURAN N., HAZNEDAROĞLU İ. C.

BLOOD COAGULATION & FIBRINOLYSIS, vol.26, no.2, pp.233-234, 2015 (SCI-Expanded)

XCIII. Clinicopathological associations of acquired erythroblastopenia

GÜNEŞ G., Malkan Ü. Y., YAŞAR H. A., ELİAÇIK E., HAZNEDAROĞLU İ. C., DEMİROĞLU H., SAYINALP N., AKSU S., ETGÜL S., Aslan T., et al.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.8, no.12, pp.22515-22519, 2015
(SCI-Expanded)

- XCIV. **Tryptophan in Molecular Hematopoiesis**
HAZNEDAROĞLU İ. C.
TRYPTOPHAN METABOLISM: IMPLICATIONS FOR BIOLOGICAL PROCESSES, HEALTH AND DISEASE, pp.253-267,
2015 (SCI-Expanded)
- XCVC. **Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms**
ELİAÇIK E., Isik A., AKSU S., ÜNER A., BÜYÜKAŞIK Y., SAYINALP N., GÖKER H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.32, no.2, pp.163-167, 2015 (SCI-Expanded)
- XCVI. **The factors affecting early death after the initial therapy of acute myeloid leukemia**
Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C., ETGÜL S., Aslan T., Yayar O., Aydın S., DEMİROĞLU H.,
ÖZCEBE O. İ., et al.
INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, vol.8, no.12, pp.22564-22569, 2015
(SCI-Expanded)
- XCVII. **Rebound Thrombocytosis following Induction Chemotherapy Is an Independent Predictor of a Good Prognosis in Acute Myeloid Leukemia Patients Attaining First Complete Remission**
Malkan Ü. Y., Gunes G., Isik A., Eliacik E., Etgul S., Aslan T., Balaban M. S., Haznedaroglu I. C., Demiroglu H., Goker H.,
et al.
ACTA HAEMATOLOGICA, vol.134, no.1, pp.32-37, 2015 (SCI-Expanded)
- XCVIII. **Massive Life-Threatening Hemorrhages Due to Toxic Oral Intake of 3750 Mg Dabigatran Etexilate As a Suicide Attempt and the Clinical Management**
GÜNEŞ G., Malkan Ü. Y., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., ÖZCEBE O. İ., GÖKER H.,
DEMİROĞLU H.
BLOOD, vol.124, no.21, 2014 (SCI-Expanded)
- XCIX. **Rebound Thrombocytosis Is an Independent Predictor of Good Prognosis in AML Patients Attaining First Complete Remission**
Malkan Ü. Y., GÜNEŞ G., GÖKER H., ELİAÇIK E., Isik A., SAYINALP N., HAZNEDAROĞLU İ. C., DEMİROĞLU H., AKSU S.,
ÖZCEBE O. İ., et al.
BLOOD, vol.124, no.21, 2014 (SCI-Expanded)
- C. **In vivo confocal microscopic characteristics of crystalline keratopathy in patients with monoclonal gammopathy: Report of two cases**
KOCABEYOĞLU S., MOCAN M. C., HAZNEDAROĞLU İ. C., ÜNER A., UZUNOSMANOĞLU E., Irkeç M.
INDIAN JOURNAL OF OPHTHALMOLOGY, vol.62, no.9, pp.938-940, 2014 (SCI-Expanded)
- CI. **Effective Management of Hemoptysis Via Endobronchial Application of Ankaferd Hemostat**
UZUN O., Erkan L., HAZNEDAROĞLU İ. C.
ARCHIVOS DE BRONCONEUMOLOGIA, vol.50, no.9, pp.407-409, 2014 (SCI-Expanded)
- CII. **Local Renin-Angiotensin System in Normal Hematopoietic and Multiple Myeloma-Related Progenitor Cells**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz O., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., GÖKER H., ÖZCEBE
O. İ., et al.
TURKISH JOURNAL OF HEMATOLOGY, vol.31, no.2, pp.136-142, 2014 (SCI-Expanded)
- CIII. **Next Generation Nanomedicine in the Genesis of "Ankaferd Blood Stopper Nanohemostat" A Novel Chimeric Topical Hemostatic Agent for Clinical Hemorrhages**
Beyazit Y., Huri E., Purnak T., GÜLER M. Ö., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.20, no.4, pp.456-457, 2014 (SCI-Expanded)
- CIV. **Ibrutinib: From Molecule to Medicine**
Ayyıldız O., Demirkan F., GÖKER H., HAZNEDAROĞLU İ. C., İlhan O., KAYNAR L., Ozdemir E., SAYDAM G., SAYINALP
N., ŞAHİN F., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.4-14, 2014 (SCI-Expanded)
- CV. **An Immune Thrombocytopenic Purpura-Like Picture Preceding Chronic Myelomonocytic Leukemia: A**

Case Series and Review of the Literature

Albayrak M., ELİAÇIK E., KORUCU B., Isik A., GÜNEŞ G., AKSU S., GÖKER H., DEMİROĞLU H., SAYINALP N., HAZNEDAROĞLU İ. C., et al.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.213-216, 2014 (SCI-Expanded)

- CVI. **Clinical Perspectives About the Molecular Management of B-Lymphoproliferative Neoplasms**
HAZNEDAROĞLU İ. C., SAYINALP N.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.1-3, 2014 (SCI-Expanded)

- CVII. **Acute in Vitro effects of Ankaferd Hemostat) on the Lymphoid Neoplastic Cells (B-CLL and RAJI Tumor Cell Lines)**

AKALIN İ., Okur F. V., HAZNEDAROĞLU İ. C., SAYINALP N., AKSU S., BÜYÜKAŞIK Y., GÖKER H.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.4, pp.253-259, 2014 (SCI-Expanded)

- CVIII. **The Efficiency of Ankaferd Blood Stopper During the Dental Surgery in Hemorrhagic Diathesis: Case Series**

AKTAŞ A., ER N., KİRİŞ S., KÖSEOĞLU O. T., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.1, pp.60-64, 2014 (SCI-Expanded)

- CIX. **As a Rare Presentation of Waldenstrom's Macroglobulinemia; Fever**

Ozen M., HAZNEDAROĞLU İ. C.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.3, pp.221-222, 2014 (SCI-Expanded)

- CX. **Clarification Letter Regarding the Gas Chromatography-Mass Spectrometry (GC-MS) Analyses of Ankaferd Hemostat, Published in UHOD 23: 171-177, 2013**

HAZNEDAROĞLU İ. C., Beyazit Y., ÖZTÜRK Y., Demiralp D. O., Iğci N.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.2, pp.148, 2014 (SCI-Expanded)

- CXI. **Co-expression of t(5;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature**

Uz B., ELİAÇIK E., Isik A., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., GÖKER H., SAYINALP N., ÖZCEBE O. İ.

TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.4, pp.400-404, 2013 (SCI-Expanded)

- CXII. **Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients**

ŞAHİN F., SAYDAM G., Comert M., Uz B., Yavuz A., Turan E., Yonal I., Atay H., Keltikli E., Turgut M., et al.

TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.4, pp.351-358, 2013 (SCI-Expanded)

- CXIII. **Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: A single center experience**

GÖKER H., Ozdemir E., UZ B., BÜYÜKAŞIK Y., Turgut M., SEREFHANOĞLU S., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., TEKİN F., et al.

TRANSFUSION AND APHERESIS SCIENCE, vol.49, no.3, pp.590-599, 2013 (SCI-Expanded)

- CXIV. **Evaluation of the mean platelet volume in secondary amyloidosis due to familial Mediterranean fever**

Ozkayar N., Piskinpasa S., Akyel F., Dede F., YILDIRIM T., Turgut D., Koc E., HAZNEDAROĞLU İ. C.

RHEUMATOLOGY INTERNATIONAL, vol.33, no.10, pp.2555-2559, 2013 (SCI-Expanded)

- CXV. **EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate**

Uz B., BÜYÜKAŞIK Y., Atay H., KELKİTLİ E., Turgut M., BEKTAŞ Ö., ELİAÇIK E., Isik A., AKSU S., GÖKER H., et al.

HEMATOLOGY, vol.18, no.5, pp.247-252, 2013 (SCI-Expanded)

- CXVI. **The Impact of Eltrombopag Administration on the Clinical Course of Severe Refractory Fatal Acquired Aplastic Anemia**

Isik A., ELİAÇIK E., HAZNEDAROĞLU İ. C., AKSU S., SAYINALP N., BÜYÜKAŞIK Y., GÖKER H., Ozcebe O.

TURKISH JOURNAL OF HEMATOLOGY, vol.30, no.3, pp.328-330, 2013 (SCI-Expanded)

- CXVII. **Long-Term Sustained Hemorrhage Due to Bone Marrow Biopsy Successfully Treated With Topical Ankaferd Hemostat in a Bleeding-Prone Patient With Secondary Amyloidosis**

Uz B., SAİN GÜVEN G., Isik A., KUYUMCU M. E., BEKTAŞ Ö., ELİAÇIK E., AKSU S., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., et al.

- CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.19, no.3, pp.338-340, 2013 (SCI-Expanded)
- CXVIII. **ULTRASTRUCTURAL ANALYSES OF THE NOVEL CHIMERIC HEMOSTATIC AGENT GENERATED VIA NANOTECHNOLOGY, ABS NANOHEMOSTAT, AT THE RENAL TISSUE LEVEL**
Huri E., HAZNEDAROĞLU İ. C., Hayran M., Ergun M., FIRAT A., Beyazit Y., Mammadov R., Guler M., Dadali M., GÖKER H.
HAEMATOLOGICA, vol.98, pp.439, 2013 (SCI-Expanded)
- CXIX. **Circulating CD4+CD25+ Regulatory T Cells in the Pathobiology of Ulcerative Colitis and Concurrent Primary Sclerosing Cholangitis**
Kekilli M., Tunc B., Beyazit Y., Kurt M., Onal I. K., Ulker A., HAZNEDAROĞLU İ. C.
DIGESTIVE DISEASES AND SCIENCES, vol.58, no.5, pp.1250-1255, 2013 (SCI-Expanded)
- CXX. **Short-Term Effects of Ankaferd Hemostat for Renal Artery Embolization: An Experimental Study**
Ozbek O., Acar K., Koc O., Saritas K., Toy H., SOLAK Y., Ozbek S., Kucukapan A., Guler I., Gaipov A., et al.
CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, vol.36, no.2, pp.498-504, 2013 (SCI-Expanded)
- CXXI. **Local bone marrow renin-angiotensin system in primitive, definitive and neoplastic haematopoiesis**
HAZNEDAROĞLU İ. C., Beyazit Y.
CLINICAL SCIENCE, vol.124, pp.307-323, 2013 (SCI-Expanded)
- CXXII. **Echocardiographic Dilemma: Misleading Thrombus Appearance Due to Cavitation With Intravascular Hemolysis on a Mechanical Prosthetic Valve**
Akpınar I., Sayin M. R., KARABAĞ T., Kalkan M. E., DOĞAN S. M., AYDIN M., HAZNEDAROĞLU İ. C.
CANADIAN JOURNAL OF CARDIOLOGY, vol.29, no.3, 2013 (SCI-Expanded)
- CXXIII. **Oral High-Dose Ankaferd Administration Effects on Gastrointestinal System**
Akbal E., KÖKLÜ S., Astarci H. M., Kocak E., Karaca G., Beyazit Y., Topcu G., Acar B., Ergun D., HAZNEDAROĞLU İ. C.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol.10, no.4, pp.451-456, 2013 (SCI-Expanded)
- CXXIV. **Bone Marrow Iron Staining is a Reliable Test for Elimination of Iron Deficiency Anemia Rather than its Diagnosis**
Koca E., Cetiner D. A., BÜYÜKAŞIK Y., ÜNER A., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., AKSU S., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.4, pp.260-263, 2013 (SCI-Expanded)
- CXXV. **Renin-Angiotensin System (RAS) Expressions in Myeloid Leukemic Cell Lines**
Uz B., Tatonyan S. C., Sayitoglu M., Erbilgin Y., Hatirnaz Ng O., BÜYÜKAŞIK Y., AKSU S., SAYINALP N., GÖKER H., ÖZCEBE O. İ., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.4, pp.264-268, 2013 (SCI-Expanded)
- CXXVI. **The Fourier Transform Infrared (FTIR) Spectroscopic and Mass Spectrometric Metabolomics Studies of Ankaferd Hemostat**
Demiralp D. O., Igci N., Ozturk Y., Beyazit Y., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.23, no.3, pp.171-177, 2013 (SCI-Expanded)
- CXXVII. **Molecular Basis of Ankaferd-Induced Hemostasis in the Management of Sternal Bleeding**
Beyazit Y., Sayilir A., Suvak B., Torun S., HAZNEDAROĞLU İ. C.
HEART SURGERY FORUM, vol.15, no.6, 2012 (SCI-Expanded)
- CXXVIII. **Prohemostatic and Antithrombin Activities of Ankaferd Hemostat Are Linked to Fibrinogen Gamma Chain and Prothrombin by Functional Proteomic Analyses**
Ozel-Demiralp D., Igci N., Ayhan B., Egin Y., HAZNEDAROĞLU İ. C., Akar N.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.18, no.6, pp.604-610, 2012 (SCI-Expanded)
- CXXIX. **Effects of Ankaferd hemostat on the synovial fluid of patients with osteoarthritis**
ÖZTÜRK M. A., KOÇAK TUFAN Z., Demirg M. D., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.42, no.5, pp.768-772, 2012 (SCI-Expanded)
- CXXX. **Increased mean platelet volume (MPV) indicating the vascular risk in Alzheimer's disease (AD)**
Yesil Y., Kuyumcu M. E., CANKURTARAN M., Uz B., Kara A., Kilic M. K., Halil M., Ulger Z., YAVUZ B. B., HAZNEDAROĞLU İ. C., et al.
ARCHIVES OF GERONTOLOGY AND GERIATRICS, vol.55, no.2, pp.257-260, 2012 (SCI-Expanded)
- CXXXI. **Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis**

- Leblebisatan G., Bay A., Karakus S. C., Kekilli M., HAZNEDAROĞLU İ. C.
BLOOD COAGULATION & FIBRINOLYSIS, vol.23, no.6, pp.494-497, 2012 (SCI-Expanded)
- CXXXII. **Controlling of upper gastrointestinal bleeding associated with severe immune thrombocytopenia via topical adjunctive application of Ankaferd blood stopper**
Ozseker B., Shorbagi A., Efe C., HAZNEDAROĞLU İ. C., BAYRAKTAR Y.
BLOOD COAGULATION & FIBRINOLYSIS, vol.23, no.5, pp.464, 2012 (SCI-Expanded)
- CXXXIII. **Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat**
Haznedaroglu B. Z., Beyazit Y., Walker S. L., HAZNEDAROĞLU İ. C.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol.83, no.1, pp.21-34, 2012 (SCI-Expanded)
- CXXXIV. **Effective Molecular Monitoring and the Proper Management of Pleural Effusion During the First-Line Dasatinib Administration in CML**
AKSU S., BEKTAŞ Ö., Uz B., BÜYÜKAŞIK Y., SAYINALP N., Ozcebe O., GÖKER H., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.1-7, 2012 (SCI-Expanded)
- CXXXV. **Unusual Extramedullary Recurrence and Renal Relapse Despite Complete Chimerysm after Allografting in Ph+ ALL**
Serefhanoglu S., GÖKER H., BAYDAR D., ÜNER A., ARICI M., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.46-50, 2012 (SCI-Expanded)
- CXXXVI. **A Placebo-Controlled, Randomized, Double-Blinded, Cross-Over Phase-I Clinical Study Indicating the Safety of Topical Ankaferd Hemostat in Healthy Volunteers**
Balcik O. S., Koroglu M., Cipil H., Kaftan O., Maral S., Gurel A., GÖKER H., HAZNEDAROĞLU İ. C., Kosar A.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.4, pp.267-274, 2012 (SCI-Expanded)
- CXXXVII. **Striking Promotion of the In Vitro Myeloma Monoclonal Immunoglobulin Aggregation by Ankaferd Hemostat**
Albayrak M., AKSU S., Celebi H., Albayrak A., Ginis Z., Yagci S., Balcik O. S., Yokus O., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.15-22, 2012 (SCI-Expanded)
- CXXXVIII. **Histopathological Alterations in the Kidney Tissue Following Topical Ankaferd Hemostat Application in a Rat Renal Injury Model**
KARAKOÇ D., Akar E., AKSU S., ÜNER A., ÖZDEMİR A., HAMALOĞLU E., Ozenc A., Dogrul A., Memedova B., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.4, pp.275-281, 2012 (SCI-Expanded)
- CXXXIX. **The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia**
AKSU S., ŞAHİN F., Uz B., Yavuz S. A., Atay H., KELKİTLİ E., Turgut M., PEHLİVAN M., Akay M. O., Guray E., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.8-14, 2012 (SCI-Expanded)
- CXL. **The effects of Ankaferd (R) Blood Stopper on transcription factors in HUVEC and the erythrocyte protein profile**
YILMAZ E., Gulec S., Torun D., HAZNEDAROĞLU İ. C., Akar N.
TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.4, pp.276-285, 2011 (SCI-Expanded)
- CXLI. **Ankaferd Blood Stopper Is More Effective Than Adrenaline Plus Lidocaine and Gelatin Foam in the Treatment of Epistaxis in Rabbits**
Kelles M., Kalcioğlu M. T., ŞAMDANCI E., Selimoglu E., Iraz M., MİMAN M. C., HAZNEDAROĞLU İ. C.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, vol.72, no.5, pp.185-194, 2011 (SCI-Expanded)
- CXLII. **Increased ACE in extrahepatic cholangiocarcinoma as a clue for activated RAS in biliary neoplasms**
Beyazit Y., Purnak T., Suvak B., Kurt M., Sayilir A., Turhan T., Tas A., Torun S., Celik T., Ibis M., et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.35, no.10, pp.644-649, 2011 (SCI-Expanded)
- CXLIII. **Percutaneous ankaferd injection to in vivo liver tissue in comparison to ethanol in an experimental rat model**
Tas A., Koklu S., Beyazit Y., Karaca G., Astarci H. M., Akbal E., Kocak E., Topcu G., HAZNEDAROĞLU İ. C.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, vol.35, pp.549-553, 2011 (SCI-Expanded)

- CXLIV. **Ankaferd hemostat in the management of gastrointestinal hemorrhages**
Beyazit Y., Kekilli M., HAZNEDAROĞLU İ. C., KAYAÇETİN E., Basaranoglu M.
WORLD JOURNAL OF GASTROENTEROLOGY, vol.17, no.35, pp.3962-3970, 2011 (SCI-Expanded)
- CXLV. **Surgical and histopathological effects of topical Ankaferd (R) hemostat on major arterial vessel injury related to elevated intra-arterial blood pressure**
Ulus A. T., TURAN DURAL N. N., Ozyalcin S., Aydog G., Ulus F., GÖKER H., HAZNEDAROĞLU İ. C.
TURKISH JOURNAL OF HEMATOLOGY, vol.28, no.3, pp.206-212, 2011 (SCI-Expanded)
- CXLVI. **Elevated Levels of Circulating Angiotensin Converting Enzyme in Patients with Hepatoportal Sclerosis**
Beyazit Y., Ibis M., Purnak T., Turhan T., Kekilli M., Kurt M., Sayilir A., Onal I. K., Turhan N., Tas A., et al.
DIGESTIVE DISEASES AND SCIENCES, vol.56, no.7, pp.2160-2165, 2011 (SCI-Expanded)
- CXLVII. **Ankaferd hemostat for the management of tumoral GI bleeding**
Beyazit Y., Kekilli M., Kurt M., Sayilir A., HAZNEDAROĞLU İ. C.
GASTROINTESTINAL ENDOSCOPY, vol.73, no.5, pp.1072-1073, 2011 (SCI-Expanded)
- CXLVIII. **Upper Gastrointestinal Bleeding in a Patient With Defective Hemostasis Successfully Treated with Ankaferd Blood Stopper**
Purnak T., Ozaslan E., Beyazit Y., HAZNEDAROĞLU İ. C.
PHYTOTHERAPY RESEARCH, vol.25, no.2, pp.312-313, 2011 (SCI-Expanded)
- CXLIX. **The Management of Chronic Myeloid Leukemia in the Era of Second Generation Tyrosine Kinase Inhibitors**
HAZNEDAROĞLU İ. C., Cetiner M., İLHAN O.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.21, no.2, pp.1-3, 2011 (SCI-Expanded)
- CL. **EVALUATION OF A HAEMOSTATIC AGENT IN RABBITS**
Turhan N., Bilgili H., Captug O., Kurt M., Shorbagi A., Beyazit Y., Kurt O. K., Kosar A., HAZNEDAROĞLU İ. C.
AFRICAN JOURNAL OF TRADITIONAL COMPLEMENTARY AND ALTERNATIVE MEDICINES, vol.8, no.1, pp.61-65, 2011 (SCI-Expanded)
- CLI. **Identification of clinical and simple laboratory variables predicting responsible gastrointestinal lesions in patients with iron deficiency anemia**
Serefhanoglu S., BÜYÜKAŞIK Y., Emmungil H., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., AKSU S., ÖZCEBE O. İ.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, vol.8, no.1, pp.30-38, 2011 (SCI-Expanded)
- CLII. **Topical Ankaferd Bloodstopper in the Management of Critical Bleedings due to Hemorrhagic Diathesis**
Turgut M., Tutkun F., Celebi N., MUĞLALI M., HAZNEDAROĞLU İ. C., GÖKER H.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.21, no.3, pp.160-165, 2011 (SCI-Expanded)
- CLIII. **Pathobiological aspects of the local bone marrow renin-angiotensin system: a review**
HAZNEDAROĞLU İ. C., Beyazit Y.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, vol.11, no.4, pp.205-213, 2010 (SCI-Expanded)
- CLIV. **Evaluation of Hemostatic Effects of Ankaferd as an Alternative Medicine**
Beyazit Y., Kurt M., Kekilli M., GÖKER H., HAZNEDAROĞLU İ. C.
ALTERNATIVE MEDICINE REVIEW, vol.15, no.4, pp.329-336, 2010 (SCI-Expanded)
- CLV. **Successful treatment of endoscopic sphincterotomy-induced early hemorrhage with application of Ankaferd Blood Stopper**
Beyazit Y., Koklu S., Akbal E., Kurt M., Kekilli M., HAZNEDAROĞLU İ. C.
GASTROINTESTINAL ENDOSCOPY, vol.72, no.6, pp.1325-1326, 2010 (SCI-Expanded)
- CLVI. **Do All Hemolytic Anemias That Occur After Mitral Valve Repair Require Surgical Treatment?**
Gungunes A., Akpınar I., Dogan M., Baser K., Yildirim I. S., HAZNEDAROĞLU İ. C.
CLINICAL CARDIOLOGY, vol.33, no.12, 2010 (SCI-Expanded)
- CLVII. **Clinical features and outcomes of 49 Turkish patients with acute promyelocytic leukemia who received ATRA and anthracyclines (PETHEMA protocol) therapy**
SEREFHANOĞLU S., BÜYÜKAŞIK Y., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., ÖZCEBE O. İ., Turgut M., Aslan R., Ozdemir E.

LEUKEMIA RESEARCH, vol.34, no.12, 2010 (SCI-Expanded)

- CLVIII. **Oral Systemic Administration of Ankaferd Blood Stopper Has No Short-Term Toxicity in an In Vivo Rabbit Experimental Model**
Bilgili H., Captug O., Kosar A., Kurt M., Kekilli M., Shorbagi A., Kurt O. K., Ozdemir O., GÖKER H., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.5, pp.533-536, 2010 (SCI-Expanded)
- CLIX. **Atraumatic Osteonecrosis After Estrogen Replacement Therapy Associated with Low Protein S Level in a Patient with Turner Syndrome**
Ureten K., Ozturk M. A., Bostanci A., Celeni O., Oezbek M., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.5, pp.599-601, 2010 (SCI-Expanded)
- CLX. **Biphasic effects of ankaferd blood stopper on renal tubular apoptosis in the rat partial nephrectomy model representing distinct levels of hemorrhage**
Huri E., HAZNEDAROĞLU İ. C., Akgul T., Astarci M., Ustun H., Germiyanoulu C.
SAUDI MEDICAL JOURNAL, vol.31, no.8, pp.864-868, 2010 (SCI-Expanded)
- CLXI. **Ultrastructural and Morphological Analyses of the In Vitro and In Vivo Hemostatic Effects of Ankaferd Blood Stopper**
HAZNEDAROĞLU B. Z., HAZNEDAROĞLU İ. C., WALKER S. L., Bilgili H., GÖKER H., Kosar A., AKTAŞ A., Captug O., Kurt M., OEZDEMİR O., et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.16, no.4, pp.446-453, 2010 (SCI-Expanded)
- CLXII. **Ankaferd Blood Stopper for Gastrointestinal Bleeding**
Kurt M., Akdogan M., Ibis M., HAZNEDAROĞLU İ. C.
JOURNAL OF INVESTIGATIVE SURGERY, vol.23, no.4, pp.239, 2010 (SCI-Expanded)
- CLXIII. **Prognostic Factors Affecting the Clinical Course of non-Hodgkin's Lymphomas**
Beyazit Y., Kekilli M., Purnak T., GÖKER H., AKSU S., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.96-102, 2010 (SCI-Expanded)
- CLXIV. **Ankaferd Blood Stopper for controlling gastrointestinal bleeding due to distinct benign lesions refractory to conventional antihemorrhagic measures**
Kurt M., Onal I. K., Akdogan M., Kekilli M., Arhan M., Sayilir A., Oztas E., HAZNEDAROĞLU İ. C.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol.24, no.6, pp.380-384, 2010 (SCI-Expanded)
- CLXV. **Functional proteomic analysis of Ankaferd (R) Blood Stopper**
Demiralp D. O., HAZNEDAROĞLU İ. C., Akar N.
TURKISH JOURNAL OF HEMATOLOGY, vol.27, no.2, pp.70-77, 2010 (SCI-Expanded)
- CLXVI. **Increased circulating soluble P-selectin in polycystic ovary syndrome**
Yildiz B. O., BOZDAĞ G., HARMANCI A., Otegen U., Boynukalin K., Vural Z., Kirazli S., HAZNEDAROĞLU İ. C., YARALI H.
FERTILITY AND STERILITY, vol.93, no.7, pp.2311-2315, 2010 (SCI-Expanded)
- CLXVII. **Antimicrobial activity of Ankaferd Blood StopperA (R) against nosocomial bacterial pathogens**
SARIBAŞ Z., ŞENER B., HAZNEDAROĞLU İ. C., Hascelik G., Kirazli S., GÖKER H.
CENTRAL EUROPEAN JOURNAL OF MEDICINE, vol.5, no.2, pp.198-202, 2010 (SCI-Expanded)
- CLXVIII. **Safety and Efficacy of Ankaferd Blood Stopper in Dental Surgery**
ERCETIN S., HAZNEDAROĞLU İ. C., Kurt M., ONAL I. K., AKTAŞ A., KURT O. K., GÖKER H., OZDEMİR O., KIRAZLI S., FIRAT H. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.1, pp.1-5, 2010 (SCI-Expanded)
- CLXIX. **Endoscopic topical application of Ankaferd Blood Stopper for neoplastic gastrointestinal bleeding: A retrospective analysis**
Kurt M., Akdogan M., Onal I. K., Kekilli M., Arhan M., Shorbagi A., AKSU S., Kurt O. K., HAZNEDAROĞLU İ. C.
DIGESTIVE AND LIVER DISEASE, vol.42, no.3, pp.196-199, 2010 (SCI-Expanded)
- CLXX. **The adhesion molecules of L-selectin and ICAM-1 in thrombocytosis and thrombocytopenia**
Ulger Z., AKSU S., Aksoy D. Y., KÖKSAL D., HAZNEDAROĞLU İ. C., Kirazi S.
PLATELETS, vol.21, no.1, pp.49-52, 2010 (SCI-Expanded)
- CLXXI. **Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature**
Serefhanoglu S., BÜYÜKAŞIK Y., GÖKER H., Akin S. C., Akin S., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.

- MEDICAL ONCOLOGY, vol.27, no.1, pp.55-58, 2010 (SCI-Expanded)
- CLXXII. **Spinal Myeloid Sarcoma in Two Non-Leukemic Patients**
Serefhanoglu S, GÖKER H., AKSU S., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
INTERNAL MEDICINE, vol.49, no.22, pp.2493-2497, 2010 (SCI-Expanded)
- CLXXIII. **The Gray-Zone Concept, Suboptimal Response to Imatinib, Shall be Removed from the ELN-CML Recommendations**
HAZNEDAROĞLU İ. C., Koca E., AKSU S., GÖKER H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.25-26, 2010 (SCI-Expanded)
- CLXXIV. **Dasatinib-Induced Tumor Lysis Syndrome and Following Hematologic Remission in Fibrotic Blastic Crisis of CML**
BEKTAŞ Ö., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., GÖKER H., ÖZCEBE O. İ.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.20, no.2, pp.13-16, 2010 (SCI-Expanded)
- CLXXV. **Retrospective Evaluation of Patients Treated with Dasatinib for Philadelphia Positive Leukemias: Turkish Experience of 16 Months**
SAYDAM G., HAZNEDAROĞLU İ. C., Temiz Y., Soysal T., Sucak G., TOMBULOĞLU M., Ozdogu H., Yavuz S., Altintas A., Ozet G., et al.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.19, no.4, pp.195-204, 2009 (SCI-Expanded)
- CLXXVI. **Topical Ankaferd Blood Stopper Administration to Bleeding Gastrointestinal Carcinomas Decreases Tumor Vascularization**
Turhan N., Kurt M., Shorbagi A., Akdogan M., HAZNEDAROĞLU İ. C.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.104, no.11, pp.2874-2877, 2009 (SCI-Expanded)
- CLXXVII. **Changes in vascular endothelial growth factor, angiopoietins, and Tie-2 levels with G-CSF stimulation in healthy donors**
Serefhanoglu S., GÖKER H., BÜYÜKAŞIK Y., Turgut M., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., Akman U., ÖZCEBE O. İ.
ANNALS OF HEMATOLOGY, vol.88, no.7, pp.667-671, 2009 (SCI-Expanded)
- CLXXVIII. **Tandem oral, rectal, and nasal administrations of Ankaferd Blood Stopper to control profuse bleeding leading to hemodynamic instability**
Kurt M., Oztas E., KURAN S., Onal I. K., Kekilli M., HAZNEDAROĞLU İ. C.
AMERICAN JOURNAL OF EMERGENCY MEDICINE, vol.27, no.5, 2009 (SCI-Expanded)
- CLXXIX. **In Vivo Hemostatic Effect of the Medicinal Plant Extract Ankaferd Blood Stopper in Rats Pretreated With Warfarin**
Cipil H. S., Kosar A., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., Ozdemir O., Koroglu M., Kirazli S., Firat H. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.3, pp.270-276, 2009 (SCI-Expanded)
- CLXXX. **The Effect of the Chernobyl Disaster on the Occurrence of Adult Acute Leukemias in Turkey**
Ozatli D., GÖKER H., Buyuhasik Y., Sayinalp N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
TURKIYE KLİNİKLERİ TIP BİLİMLERİ DERGİSİ, vol.29, no.2, pp.388-394, 2009 (SCI-Expanded)
- CLXXXI. **The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model**
Kosar A., Cipil H. S., Kaya A., Uz B., HAZNEDAROĞLU İ. C., GÖKER H., Ozdemir O., Ercetin S., Kirazli S., Firat H. C.
BLOOD COAGULATION & FIBRINOLYSIS, vol.20, no.3, pp.185-190, 2009 (SCI-Expanded)
- CLXXXII. **In Vitro Anti-Bacterial Activities of Ankaferd Medicinal Plant Extract**
Akkoc N., AKÇELİK M., HAZNEDAROĞLU İ. C., GÖKER H., Turgut M., AKSU S., Kirazli S., Firat H. C.
TURKIYE KLİNİKLERİ TIP BİLİMLERİ DERGİSİ, vol.29, no.2, pp.410-415, 2009 (SCI-Expanded)
- CLXXXIII. **MOLECULAR BASIS OF THE PLEIOTROPIC EFFECTS OF ANKAFERD BLOOD STOPPER**
HAZNEDAROĞLU İ. C.
IUBMB LIFE, vol.61, no.3, pp.290, 2009 (SCI-Expanded)
- CLXXXIV. **Multiple Bulky Cutaneous Plasmacytomas with CNS Relapse without Bone Marrow Involvement during the Course of a Lambda Light Chain Myeloma**
Serefhanoglu S., HAZNEDAROĞLU İ. C., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
ONKOLOGIE, vol.32, no.11, pp.662-664, 2009 (SCI-Expanded)

- CLXXXV. **Thrombomodulin and GFC levels in Legg-Calve-Perthes disease**
AKSOY M. C., Aksoy D. Y., HAZNEDAROĞLU İ. C., Sayinalp N., Kirazli S., Alpaslan M.
HEMATOLOGY, vol.13, no.6, pp.324-328, 2008 (SCI-Expanded)
- CLXXXVI. **Haemostatic actions of the folkloric medicinal plant extract Ankaferd Blood Stopper Response**
HAZNEDAROĞLU İ. C., GÖKER H.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.36, no.6, pp.1448-1449, 2008 (SCI-Expanded)
- CLXXXVII. **Successful Management of Bleeding Due to Solitary Rectal Ulcer via Topical Application of Ankaferd Blood Stopper**
Ibis M., Kurt M., Onal I. K., HAZNEDAROĞLU İ. C.
JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, vol.14, no.9, pp.1073-1074, 2008 (SCI-Expanded)
- :LXXXVIII. **Effect of platelet count on secretion capacity: formulization and use of the formulae for evaluation of platelet secretion in thrombocytopenic patients**
BÜYÜKAŞIK Y., GÖKER H., Buyukasik N. S., SAYINALP N., HAZNEDAROĞLU İ. C., Ozcebea O. I.
BLOOD COAGULATION & FIBRINOLYSIS, vol.19, no.7, pp.633-637, 2008 (SCI-Expanded)
- CLXXXIX. **Extramedullary plasmacytomas of the thyroid and pericardium as initial presentation of multiple myeloma**
Serefhanoglu S., SAYINALP N., HAZNEDAROĞLU İ. C., GÖKER H., Cetiner D., AKSU S., BÜYÜKAŞIK Y., ÖZCEBE O. İ.
ANNALS OF HEMATOLOGY, vol.87, no.10, pp.853-854, 2008 (SCI-Expanded)
- CXC. **Endoscopic application of Ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: A case report**
Kurt M., Disibeyaz S., Akdogan M., Sasmaz N., AKSU S., HAZNEDAROĞLU İ. C.
AMERICAN JOURNAL OF GASTROENTEROLOGY, vol.103, no.8, pp.2156-2158, 2008 (SCI-Expanded)
- CXCI. **Severe arterial thrombophilia associated with a homozygous MTHFR gene mutation (A1298C) in a young man with Klinefelter syndrome**
Ozbek M., Ozturk M. A., Ureten K., Ceneli O., ERDOĞAN M., HAZNEDAROĞLU İ. C.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.14, no.3, pp.369-371, 2008 (SCI-Expanded)
- CXCII. **Evidence for higher red blood cell mass in persons with unconjugated Hyperbilirubinemia and Gilbert's syndrome**
BÜYÜKAŞIK Y., Akman U., Buyukasik N. S., GÖKER H., Kilicarslan A., Shorbagi A. I., Hascelik G., HAZNEDAROĞLU İ. C.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol.335, no.2, pp.115-119, 2008 (SCI-Expanded)
- CXCIII. **Soluble platelet glycoprotein V in distinct disease states of pathological thrombopoiesis**
Acar K., AKSU S., Beyazit Y., HAZNEDAROĞLU İ. C., Koca E., Cetiner D., Sayinalp N., BÜYÜKAŞIK Y., GÖKER H., Kirazli S., et al.
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, no.1, pp.86-90, 2008 (SCI-Expanded)
- CXCIV. **Change in Blood Coagulation Parameters After Total Body Irradiation**
CENGİZ M., GOEKER H., Yazici G., ZORLU F., BUEYUEKASIK Y., KIRAZLI S., AKMAN U., YILDIZ F., DOĞAN A., HAZNEDAROĞLU İ. C.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.18, no.3, pp.135-140, 2008 (SCI-Expanded)
- CXCV. **Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis**
HALİL M. G., Cankurtaran M., DOĞU B. B., Ulger Z., Piskinpasa S., Gedik A., Haznedaroglu I. C., Kirazli S., Ariogul S.
ANNALS OF PHARMACOTHERAPY, vol.41, no.1, pp.41-45, 2007 (SCI-Expanded)
- CXCVI. **The search for a common thrombophilic state during the active state of inflammatory bowel disease**
Yurekli B. P. S., Aksoy D. Y., Aybar M., Egesel T., Gurgey A., Hascelik G., Kirazli S., Haznedaroglu I. C., Arslan S.
JOURNAL OF CLINICAL GASTROENTEROLOGY, vol.40, no.9, pp.809-813, 2006 (SCI-Expanded)
- CXCVII. **Lack of association between familial Mediterranean fever and angiotensin converting enzyme gene polymorphism**
Calguneri O., Ozturk M., Kiraz S., Ertenli I., Onat A., Ureten K., Ozbalkan Z., Haznedaroglu I.
JOINT BONE SPINE, vol.73, no.3, pp.334-336, 2006 (SCI-Expanded)
- CXCVIII. **Changing clinical manifestations of a T-peripheral lymphoma: From hypereosinophilic syndrome to questionable Kimura's disease resulting in parotid mass**
Beyazit Y., Haznedaroglu I., Aksu S., Kekilli M., ÜNER A., Agbaht K., Sungur A., Koca E., Goker H., Ozcebe O.

LEUKEMIA & LYMPHOMA, vol.47, no.2, pp.357-360, 2006 (SCI-Expanded)

- CXCIX. **Myocardial infarction and deep venous thrombosis in a young patient with Behcet disease**
Calguneri M., Aydemir K., Ozturk M., Haznedaroglu I., Kiraz S., Ertenli I.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.12, no.1, pp.105-109, 2006 (SCI-Expanded)
- CC. **Rethinking leptin and insulin action: Therapeutic opportunities for diabetes**
Yildiz B., Haznedaroglu I.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol.38, pp.820-830, 2006 (SCI-Expanded)
- CCI. **Overt gastrointestinal bleeding in haematologic neoplasms**
Soylu A., Buyukasik Y., Cetiner D., Buyukasik N., Koca E., Haznedaroglu I., Ozcebe O., Simsek H.
DIGESTIVE AND LIVER DISEASE, vol.37, no.12, pp.917-922, 2005 (SCI-Expanded)
- CCII. **Complete cytogenetic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation**
Koca E., Cetiner D., Goker H., Aksu S., Ozcebe O., Haznedaroglu I., Turgan C.
CLINICAL NEPHROLOGY, vol.64, no.4, pp.324-326, 2005 (SCI-Expanded)
- CCIII. **Increased soluble glycoprotein V concentration during the acute onset of unstable angina pectoris in association with chronic cigarette smoking**
Atalar E., Haznedaroglu I., Kilic H., Ozer N., Coskun S., Ozturk E., Aksoyek S., Ovunc K., Kirazli S., Ozmen F.
PLATELETS, vol.16, no.6, pp.329-333, 2005 (SCI-Expanded)
- CCIV. **No alteration in the PFA-100 in vitro bleeding time induced by the Ginkgo biloba special extract, EGb 761, in elderly patients with mild cognitive impairment**
Halil M. G., CANKURTARAN M., YAVUZ B., OZKAYAR N., ULGER Z., DEDE D., SHORBAGI A., BUYUKASIK Y., HAZNEDAROGLU I., ARIOGUL S.
BLOOD COAGULATION & FIBRINOLYSIS, vol.16, no.5, pp.349-353, 2005 (SCI-Expanded)
- CCV. **Enhanced tissue factor pathway inhibitor response as a defense mechanism against ongoing local microvascular events of Legg-Calve-Perthes disease**
Cemalettin M., Aksoy D., Haznedaroglu I., Sayinalp N., Kirazli S., Alpaslan M.
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.22, no.5, pp.391-399, 2005 (SCI-Expanded)
- CCVI. **Immediate effects of fluvastatin on circulating soluble endothelial protein C and free tissue factor pathway inhibitor in acute coronary syndromes**
Atalar E., Coskun S., Haznedaroglu I., Yucel N., Ozer N., Sivri B., Aksoyek S., Ovunc K., Ozmen F.
CARDIOVASCULAR DRUGS AND THERAPY, vol.19, no.3, pp.177-181, 2005 (SCI-Expanded)
- CCVII. **Endogenous thrombopoietin levels during the clinical management of acute myeloid leukaemia**
GÖNEN C., Haznedaroglu I., Aksu S., Koca E., Goker H., Buyukasik Y., Sayinalp N., Ozcebe O., Dondar S.
PLATELETS, vol.16, no.1, pp.31-37, 2005 (SCI-Expanded)
- CCVIII. **Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?**
Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KIRAZLI Ş., Celik I.
ANNALS OF ONCOLOGY, vol.15, no.11, pp.1622-1626, 2004 (SCI-Expanded)
- CCIX. **Successful treatment of rheumatoid arthritis is associated with a reduction in serum sE-selectin and thrombomodulin level**
Cobankara V., Ozath D., Kiraz S., ÖZTÜRK A., Ertenli I., Turk T., Apras S., Haznedaroglu I., Calguneri M.
CLINICAL RHEUMATOLOGY, vol.23, no.5, pp.430-434, 2004 (SCI-Expanded)
- CCX. **Plasma basic fibroblast growth factor and bone marrow fibrosis in clonal myeloproliferative disorders**
Sayinalp N., Cinar H., ÜNER A., Haznedaroglu I., Buyukasik Y., Goker H., Aksu S., Ozcebe O., Karakus S., Kirazli S., et al.
CLINICAL AND LABORATORY HAEMATOLOGY, vol.26, no.4, pp.265-268, 2004 (SCI-Expanded)
- CCXI. **The predictability of factor V Leiden (FV : Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance**
Sayinalp N., Haznedaroglu I., Aksu S., Buyukasik Y., Goker H., Parlak H., Ozcebe O., Kirazli S., Dundar S., Gurgey A.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.10, no.3, pp.265-270, 2004 (SCI-Expanded)
- CCXII. **Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia**

- Dizdar O, Yurekli B, Purnak T, Aksu S, Haznedaroglu I.
ANNALS OF PHARMACOTHERAPY, vol.38, pp.1319-1320, 2004 (SCI-Expanded)
- CCXIII. **Current debates in antiphospholipid syndrome: The acquired antibody-mediated thrombophilia**
Ozturk M, Haznedaroglu I, Turgut M, Goker H.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.10, no.2, pp.89-126, 2004 (SCI-Expanded)
- CCXIV. **Angiotensin-converting enzyme gene polymorphism in Behcet's disease**
Ozturk M, Calguneri M, Kiraz S, Ertenli I, Onat A, Ureten K, Ozbalkan Z, Haznedaroglu I.
CLINICAL RHEUMATOLOGY, vol.23, no.2, pp.142-146, 2004 (SCI-Expanded)
- CCXV. **Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behcet's disease**
Ozturk M, Ertenli I, Kiraz S, Haznedaroglu I, Celik I, Kirazli S, Calguneri M.
RHEUMATOLOGY INTERNATIONAL, vol.24, no.2, pp.98-102, 2004 (SCI-Expanded)
- CCXVI. **How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems**
Ozturk M, Guven G, Haznedaroglu I.
MEDICAL HYPOTHESES, vol.63, no.5, pp.866-874, 2004 (SCI-Expanded)
- CCXVII. **Protein C inhibitor and serum amyloid A in immune thrombocytopaenic purpura**
Sayinalp N, Haznedaroglu I, Buyukasik Y, Goker H, Aksu S, Kocoglu H, Ozcebe O, Kosar A, Kirazli S, Dundar S.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.32, no.1, pp.62-65, 2004 (SCI-Expanded)
- CCXVIII. **Patients with paroxysmal atrial fibrillation but not paroxysmal supraventricular tachycardia display evidence of platelet activation during arrhythmia**
Atalar E, Haznedaroglu I, Acil T, Ozer N, Kilic H, Ovunc K, Aksoyek S, Nazli N, Kes S, Kabakci G., et al.
PLATELETS, vol.14, pp.407-411, 2003 (SCI-Expanded)
- CCXIX. **Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis**
Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk M, Haznedaroglu I, Cobankara V, Pay S, Calguneri M.
ARTHRITIS AND RHEUMATISM, vol.48, no.8, pp.2256-2261, 2003 (SCI-Expanded)
- CCXX. **Decreased protein Z concentrations complicating the hypercoagulable state of Behcet's disease**
Ozturk M, Ozbalkan Z, Onat A, Ertenli I, Kiraz S, Aytemir K, Ureten K, Abali G, Calguneri M, Kirazli E., et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.9, no.3, pp.259-263, 2003 (SCI-Expanded)
- CCXXI. **Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system**
Haznedaroglu I, Ozturk M.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol.35, no.6, pp.867-880, 2003 (SCI-Expanded)
- CCXXII. **Pathologic thrombopoiesis of rheumatoid arthritis**
Ertenli I, Kiraz S, Ozturk M, Haznedaroglu I, Celik I, Calguneri M.
RHEUMATOLOGY INTERNATIONAL, vol.23, no.2, pp.49-60, 2003 (SCI-Expanded)
- CCXXIII. **Increased soluble FAS suggests delayed apoptosis in familial Mediterranean fever complicated with amyloidosis**
Kiraz S, Ertenli I, Ozturk M, Haznedaroglu I, Calguneri M, Atalar E, Ozbalkan Z, Kirazli S, Celik I.
JOURNAL OF RHEUMATOLOGY, vol.30, no.2, pp.313-315, 2003 (SCI-Expanded)
- CCXXIV. **Bloodstream thrombopoietin in rheumatoid arthritis with thrombocytosis**
Kiraz S, Ertenli I, Ozturk M, Haznedaroglu I, Celik I, Kirazli S, Calguneri M.
CLINICAL RHEUMATOLOGY, vol.21, no.6, pp.453-456, 2002 (SCI-Expanded)
- CCXXV. **Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension**
Haznedaroglu I, Atalar E, Ozturk M, Ozer N, Ovunc K, Aksoyek S, Kes S, Kirazli S, Ozmen F.
PLATELETS, vol.13, no.7, pp.395-399, 2002 (SCI-Expanded)
- CCXXVI. **Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists**
Abali H, Gullu I, Engin H, Haznedaroglu I, Erman M, Tekuzman G.
MEDICAL HYPOTHESES, vol.59, no.3, pp.344-348, 2002 (SCI-Expanded)
- CCXXVII. **Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic**

state

Yildiz B., Haznedaroglu I., Kirazli S., Bayraktar M.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol.87, no.8, pp.3871-3875, 2002 (SCI-Expanded)

CCXXVIII. **Thrombopoietin as a drug: Biologic expectations, clinical realities, and future directions**

Haznedaroglu I., Goker H., Turgut M., Buyukasik Y., Benekli M.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.8, no.3, pp.193-212, 2002 (SCI-Expanded)

CCXXIX. **Rational use of the PFA-100 device for screening of platelet function disorders and von Willebrand disease**

Buyukasik Y., Karakus S., Goker H., Haznedaroglu I., Ozatli D., Sayinalp N., Ozcebe O., Dundar S., Kirazli S.

BLOOD COAGULATION & FIBRINOLYSIS, vol.13, no.4, pp.349-353, 2002 (SCI-Expanded)

CCXXX. **Hemostatic parameters in Behcet's disease: a reappraisal**

Kosar A., Ozturk M., Haznedaroglu I., Karaaslan Y.

RHEUMATOLOGY INTERNATIONAL, vol.22, no.1, pp.9-15, 2002 (SCI-Expanded)

CCXXXI. **Proinflammatory and hematopoietic cytokines in reactive and clonal thrombocytosis**

Ozturk M., Kiraz S., Ertenli I., Calguneri M., Haznedaroglu I.

SOUTHERN MEDICAL JOURNAL, vol.95, no.5, pp.565-566, 2002 (SCI-Expanded)

CCXXXII. **Piebaldism associated with congenital dyserythropoietic anemia type II (HEMPAS)**

Koklu S., Ertugrul D., Onat A., Karakus S., Haznedaroglu I., Buyukasik Y., Sayinalp N., Ozcebe O., Dundar S.

AMERICAN JOURNAL OF HEMATOLOGY, vol.69, no.3, pp.210-213, 2002 (SCI-Expanded)

CCXXXIII. **Plasma thrombospondin in immune thrombocytopenic purpura**

Ozcebe O., Karakus S., Haznedaroglu I., Goker H., Kosar A., Kocoglu H., Buyukasik Y., Sayinalp N., Kirazli S.

JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, vol.30, no.1, pp.52-55, 2002 (SCI-Expanded)

CCXXXIV. **Effects of extracorporeal circulation on thrombin-antithrombin III and prothrombin fragment 1+2 levels**

Yilmaz M., Haznedaroglu I., Kirazli S., Pasaoglu I.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.8, no.1, pp.61-63, 2002 (SCI-Expanded)

CCXXXV. **Pathological haemostasis and 'prothrombotic state' in Behcet's disease**

Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Celik I., Calguneri M.

THROMBOSIS RESEARCH, vol.105, no.2, pp.125-133, 2002 (SCI-Expanded)

CCXXXVI. **Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Behcet's disease: evidence of a prethrombotic state**

Ozatli D., Sayinalp N., Buyukasik Y., Karakus S., Haznedaroglu I., Kirazli S., Ozcebe O., Dundar S.

RHEUMATOLOGY INTERNATIONAL, vol.21, no.4, pp.137-140, 2002 (SCI-Expanded)

CCXXXVII. **Plasma thrombopoietin in patients with cavernous transformation of the portal vein**

Goker H., Egesel T., Karakus S., Haznedaroglu I., Apras S., Buyukasik Y., Sayinalp N., Ozcebe O., Dundar S., Kirazli S., et al.

INTERNATIONAL JOURNAL OF HEMATOLOGY, vol.75, no.1, pp.91-94, 2002 (SCI-Expanded)

CCXXXVIII. **Hyperhomocysteinaemia and activated protein C resistance in Behcet's disease**

Altinbas A., Aytemur K., Tokgozoglul., Ozturk M., Kosar A., Haznedaroglu I., Kirazli S., Dundar S.

JOURNAL OF INTERNAL MEDICINE, vol.248, no.3, pp.267-268, 2000 (SCI-Expanded)

CCXXXIX. **The plasma levels of prostanoids and plasminogen activator inhibitor-1 in primary and secondary thrombocytosis**

Birdane A., Haznedaroglu I., Ozath D., Sayinalp N., Kosar A., Buyukasik Y., Ozcebe O., Karakus S., Dundar S., Kirazli S.

EXPERIMENTAL HEMATOLOGY, vol.28, no.7, pp.120, 2000 (SCI-Expanded)

CCXL. **Behcet's disease.**

Haznedaroglu I., Ozcebe O., Dundar S.

NEW ENGLAND JOURNAL OF MEDICINE, vol.342, no.8, pp.588, 2000 (SCI-Expanded)

CCXLI. **A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway**

Haznedaroglu I., Arici M., Buyukasik Y.

MEDICAL HYPOTHESES, vol.54, no.1, pp.80-83, 2000 (SCI-Expanded)

- CCXLII. **Serum L-selectin and P-selectin levels in lymphomas**
Haznedaroglu I, Benekli M, Ozcebe O, Savas M, Gullu IH G. I, Dundar S, Kirazli S.
HAEMATOLOGIA, vol.30, no.1, pp.27-30, 2000 (SCI-Expanded)
- CCXLIII. **Aplastic pancytopenia associated with thymoma [2]**
Coplu L., Selcuk Z., Haznedaroglu I., Dogan R., Gungen Y.
Annals of Hematology, vol.79, no.11, pp.648-650, 2000 (SCI-Expanded)
- CCXLIV. **Selectin adhesion molecules in Behcet's disease**
Haznedaroglu S, Karaaslan Y., Buyukasik Y., Kosar A., Ozcebe O., Haznedaroglu I., Kirazli S., Dundar S.
ANNALS OF THE RHEUMATIC DISEASES, vol.59, no.1, pp.61-63, 2000 (SCI-Expanded)
- CCXLV. **Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever**
KIRAZ S., ERTENLİ A. İ., ARICI M., Calguneri M., HAZNEDAROĞLU İ. C., ÇELİK İ., PAY S., Kirazli S.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, vol.16, no.6, pp.721-724, 1998 (SCI-Expanded)

Articles Published in Other Journals

- I. **IMMUNOGENOMIC APPROACH TO THE CLINICAL MANAGEMENT OF COVID-19 SYNDROME**
TÜRK S., HAZNEDAROĞLU İ. C., TÜRK C., Malkan Ü. Y.
Eskisehir Medical Journal, Eskisehir City Hospital, 2023 (Peer-Reviewed Journal)
- II. **Pharmacobiology of topical Ankaferd hemostat in neoplastic disorders**
Malkan U. Y., Haznedaroglu I. C.
The European Research Journal, vol.9, no.5, pp.1271-1276, 2023 (Peer-Reviewed Journal)
- III. **Exploring the distribution and prognostic effect of the ABO blood types of COVID-19 patients during delta and omicron waves: A case control study**
GÖKER H., ÇINAR O. E., ISMAYILOV R., Özdemir E., MALKAN Ü. Y., ALADAĞ E., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ., ÖZCEBE O., et al.
Acta Medica, vol.54, no.2, pp.97-102, 2023 (Peer-Reviewed Journal)
- IV. **Exposure of Hepatocellular Carcinoma Cells to Ankaferd Blood Stopper (R) Alters Cell Death Signaling Networks Confirmed by Oncoproteomic and Genomic Profiling Studies**
NENNİ M., ÖNCÜL S., ERCAN A., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.
CURRENT TRADITIONAL MEDICINE, vol.7, no.2, pp.223-235, 2021 (ESCI)
- V. **Pharmacobiological management of hemostasis within clinical backgrounds via Ankaferd hemostat (Ankaferd blood stopper)**
Ciftçiler R., Ciftçiler A. E., Malkan Ü. Y., HAZNEDAROĞLU İ. C.
SAGE OPEN MEDICINE, vol.8, 2020 (ESCI)
- VI. **Comparison of bortezomib-cyclophosphamide-dexamethasone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients**
Ciftçiler R., GÖKER H., BÜYÜKAŞIK Y., SAYINALP N., HAZNEDAROĞLU İ. C., AKSU S., Ozcebe O., DEMİROĞLU H.
HEMATOLOGY REPORTS, vol.12, no.1, 2020 (ESCI)
- VII. **Effects of Smoking on Hematological Parameters and Ferritin Levels**
Ciftçiler R., Guven A., HAZNEDAROĞLU İ. C., AKSU S.
HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI, vol.57, no.4, pp.372-376, 2019 (ESCI)
- VIII. **CYTOGENETIC ANOMALIES IN MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER STUDY**
BOZKURT S., BÜYÜKAŞIK Y., DEMİROĞLU H., ALADAĞ KARAKULAK E., OKAY M., KARATAŞ A., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
Genetics and Application, vol.3, no.1, pp.51-56, 2019 (Peer-Reviewed Journal)
- IX. **Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome**
ÇİFTÇİLER R., SAĞLAM E. A., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C.
Medical Science and Discovery, vol.5, no.12, pp.390-392, 2018 (Peer-Reviewed Journal)
- X. **Evaluation of Secondary Malignancies in Chronic Lymphocytic Leukemia**

DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., OKAY M., ÇİFTÇİLER R., heziyev t

Journal of Global Oncology, pp.205, 2018 (ESCI)

- XI. **Farklı Trombositopeni Sebeplerinin Klinik ve Laboratuvar Bulguları**
AKIN S., AKIN Ş., Karaağaç A. T., HAZNEDAROĞLU İ. C.
Journal of Contemporary Medicine, vol.7, no.4, pp.316-322, 2017 (Peer-Reviewed Journal)
- XII. **Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper**
ŞİMŞEK C., Selek S., Koca M., HAZNEDAROĞLU İ. C.
SAGE OPEN MEDICINE, vol.5, 2017 (ESCI)
- XIII. **Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines**
TÜRK TÜRK S., Malkan Ü. Y., Ghasemi M., Hocaoglu H., Mutlu D., Gunes G., AKSU S., HAZNEDAROĞLU İ. C.
SAGE OPEN MEDICINE, vol.5, 2017 (ESCI)
- XIV. **Treatment of pyoderma gangrenosum with thalidomide in a myelodysplastic syndrome case**
Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., HAZNEDAROĞLU İ. C.
INTERNATIONAL MEDICAL CASE REPORTS JOURNAL, vol.9, pp.61-64, 2016 (ESCI)
- XV. **Melanonychia Secondary to Long-Term Treatment with Hydroxycarbamide: An Essential Thrombocytosis Case**
Malkan Ü. Y., GÜNEŞ G., ELİAÇIK E., Yayar O., HAZNEDAROĞLU İ. C.
CASE REPORTS IN HEMATOLOGY, 2015 (ESCI)
- XVI. **Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)**
HAZNEDAROĞLU İ. C.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, vol.6, no.1, 2014 (ESCI)
- XVII. **Generation of Chimeric "ABS Nanohemostat" Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model**
Huri E., Beyazit Y., Mammadov R., Toksoz S., TEKİNAY A. B., GÜLER M. Ö., Ustun H., Kekilli M., Dadali M., Celik T., et al.
INTERNATIONAL JOURNAL OF BIOMATERIALS, vol.2013, 2013 (ESCI)
- XVIII. **THE FACTORS INFLUENCING OVERALL SURVIVAL IN NEWLY DIAGNOSED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS**
Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetgner D., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISİ, vol.74, no.1, pp.7-12, 2011 (ESCI)
- XIX. **DISEASE CHARACTERISTICS AND FACTORS INFLUENCING TREATMENT RESPONSE IN NEWLY DIAGNOSED ACUTE MYELOBLASTIC LEUKEMIA PATIENTS: A SINGLE CENTER EXPERIENCE**
Serefhanoglu S., BÜYÜKAŞIK Y., AKSU S., GÖKER H., SAYINALP N., Cetiner D., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
JOURNAL OF ISTANBUL FACULTY OF MEDICINE-ISTANBUL TIP FAKULTESİ DERGISİ, vol.73, no.3, pp.74-79, 2010 (ESCI)

Books & Book Chapters

- I. **HMGB1-targeting herbal medicinal plant extracts for the phytotherapy of cancer and potential management of COVID-19**
REÇBER T., HAZNEDAROĞLU İ. C., ÇELEBİER M.
in: HMGB1: Functions, Inhibitors, and Clinical Significance, TAŞKIN EYLEM, GÜVEN CELAL, KAYA SALİH TUNÇ, Editor, Nova Science Publishers, pp.3-42, 2022
- II. **Klinik Pratikte Hematoloji**
HAZNEDAROĞLU İ. C., TURGUT M., GÖKER H., BÜYÜKAŞIK Y.
nobel tıp kitabevleri, Ankara, 2019

Refereed Congress / Symposium Publications in Proceedings

- I. **Determination of Drug Sensitivity Subgroups in Acute Myeloblastic Leukemia by the Detection of Gene Based Cancer Biomarkers and the Prediction of Prognosis and Treatment.**
TÜRK TÜRK S., TÜRK C., HAZNEDAROĞLU İ. C., SAYINALP N.
The Febs Congress, 6 - 11 July 2019
- II. **Proteomic Investigation of In-Vitro Antineoplastic Effect of Ankaferd Hemostat with 2D Gel Electrophoresis and MALDI-TOF/TOF-MS in HepG2, Caco-2 and HT-29 Cancer Cells**
NENNİ M., ÇELEBİER M., SÜSLÜ İ., HAZNEDAROĞLU İ. C.
The International Society on Thrombosis and Hemostasis (ISTH), 6 - 10 July 2019
- III. **Proteomic Investigation of Ankaferd Hemostat Application on MCF-7 Breast Cancer Cell Line**
ZEKİ Ö. C., NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., HAZNEDAROĞLU İ. C.
International Multidisciplinary Symposium on Drug Research and Development (DRD), 1 - 03 July 2019
- IV. **THE EVALUATION OF THE CLINICOPATHOLOGIC CHARACTERISTICS OF T-CELL NON-HODGKIN'S LYMPHOMA: THE SINGLE CENTER EXPERIENCE**
SAYINALP N., ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., AKSU S., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ.
15th International Conference on Malignant Lymphoma, Switzerland, 18 - 22 June 2019, vol.37, pp.366
- V. **ASEMPTOMATİK D-DİMER YÜKSEKLİĞİ İMMÜNMONULATUAR KULLANAN MULTİPLE MYELOMADA TROMBOZU TAHMİN EDER Mİ: GERÇEK YAŞAM VERİSİ**
AYDIN M. S., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., YAZGAN S. Ç., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., AKSU S., GÖKER H.
4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Cyprus (Kktc), 4 - 06 April 2019
- VI. **ALLOJENİK KÖK HÜCRE NAKLİ SONRASI RELAPS İZLENEN AKUT LÖSEMİ HASTALARINDA TEDAVİ SEÇENEKLERİ: DONÖR LENFOSİT İNFUZYONU VE İKİNCİ ALLOJENİK KÖK HÜCRE NAKLİNİN KARŞILAŞTIRILMASI**
ALADAĞ KARAKULAK E., DEMİROĞLU H., BÜYÜKAŞIK Y., OKAY M., ÇİFTÇİLER R., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., TURGUT M., et al.
4. ULUSAL KAN VE KEMİK İLİĞİ NAKLİ KONGRESİ, Cyprus (Kktc), 4 - 06 April 2019
- VII. **MULTİPLE MYELOM HASTALARINDA İNDUKSİYON TEDAVİ SÜRESİNİN SAĞKALIMA ETKİSİ**
ALADAĞ KARAKULAK E., OKAY M., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.
3. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Turkey, 8 - 09 March 2019
- VIII. **Long-Term Results of Non-Fludarabine Versus Fludarabine-Based Conditioning Regimens in Severe Aplastic Anemia Patients**
ALADAĞ KARAKULAK E., DEMİROĞLU H., Ciftciler R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., Ozcebe O., Chao N. J., GÖKER H.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132
- IX. **DASATİNİB KULLANIRKEN PLEVRAL EFFÜZYONU GELİŞİP, KÜÇÜK HÜCRELİ AKCİĞER KANSERİ TANISI ALAN BİR OLGU**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., SAYINALP N., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., AKSU S., GÖKER H., BÜYÜKAŞIK Y., DEMİROĞLU H.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.364-365
- X. **MRG'DE TESADÜFEN SAPTANAN KEMİK İLİĞİNİN DİFFÜZ SİNYAL DEĞİŞİKLİKLERİ LENFOHEMATOPOETİK HASTALIKLARI ÖNGÖREBİLİR Mİ?**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., DEMİROĞLU H., GÖKER H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.266
- XI. **LENALIDOMİD İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİBE KIYASLA DAHA İYİ İLERLEMESİZ SAĞKALIM**

DEMİROĞLU H., AKSU S., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÜNEŞ G., malkan Ü. Y.

TÜRK HEMATOLOJİ DERNEĞİ, Turkey, 31 October - 03 November 2018

- XII. **LENALİDOMİD İLE MYELOMDA OTOLOG NAKİL SONRASI İLK NÜKSDE TALİDOMİD VE BORTEZOMİB'E KİYASLA DAHA İYİ İLERLEMESİZ SAĞKALIM**
MALKAN Ü. Y., BÜYÜKAŞIK Y., DEMİROĞLU H., ÇİFTÇİLER R., GÜNEŞ G., OKAY M., ALADAĞ KARAKULAK E., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., et al.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.191-192
- XIII. **AĞIR APLASTİK ANEMİ HASTALARINDA HEMATOPOETİK KÖK HÜCRE NAKLİNDE KULLANILAN HAZIRLIK REJİMLERİNİN KARŞILAŞTIRILMASI**
ALADAĞ KARAKULAK E., DEMİROĞLU H., ÇİFTÇİLER R., BÜYÜKAŞIK Y., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., ÖZCEBE O. İ., GÖKER H.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.261
- XIV. **PRİMER VE EDİNSEL İMMÜN YETMEZLİĞİ OLAN HASTALARDA MALİGNİTE SIKLIĞI**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., SAYINALP N.
44. ULUSAL HEMATOLOJİ KONGRESİ, Antalya, Turkey, 31 October - 03 November 2018, pp.276-277
- XV. **T HÜCRELİ LENFOMA HASTALARININ KLİNİK ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ: TANIDAN PROGNOZA TEK MERKEZ DENEYİMİ**
DEMİROĞLU H., SAYINALP N., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., OKAY M., ALADAĞ KARAKULAK E., ÇİFTÇİLER R.
TÜRK HEMATOLOJİ DERNEĞİ, Turkey, 31 October - 03 November 2018
- XVI. **Retrospective and multicenter analysis of efficacy and safety of ruxolitinib in 176 Turkish patient with myelofibrosis: updated data**
SOYER N., ALI R., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., PIR A., KARAKUŞ V., ÖZGÜR G., KIŞ C., et al.
9. International Eurasian Hematology Oncology Congress, 17 - 20 October 2018
- XVII. **BRENTIXUMAB VEDOTIN IN CD30 LYMPHOMAS: SINGLE CENTER EXPERIENCE**
DEMİROĞLU H., SAYINALP N., BÜYÜKAŞIK Y., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., GÖKER H., ÇİFTÇİLER R., OKAY M.
IX. INTERNATIONAL EHOC, 17 - 20 October 2018, vol.73
- XVIII. **Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., ÇİFTÇİLER R., Aladag E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Turkey, 17 - 20 October 2018, vol.73
- XIX. **Descriptive analysis of myeloproliferative diseases and its complications**
OKAY M., MALKAN Ü. Y., BÖLEK E. Ç., Aladag E., HAZİYEV T., SAYINALP N., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C.
9th International Eurasian Hematology Oncology Congress (EHOC), İstanbul, Turkey, 17 - 20 October 2018, vol.73
- XX. **RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANTRON-MELFALAN HAZIRLAMA REJİMİ**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., malkan Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
6. HEMATOLOJİK ONKOLOJİ KONGRESİ, Turkey, 18 - 22 September 2018
- XXI. **RELAPS/REFRAKTER LENFOMADA OTOLOG KÖK HÜCRE TRANSPLANTASYONUNDA MİTOKSANTRON-MELFALAN HAZIRLAMA REJİMİ**
OKAY M., BÜYÜKAŞIK Y., DEMİROĞLU H., MALKAN Ü. Y., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., et al.
5. HEMATOLOJİK ONKOLOJİ KONGRESİ, Cyprus (Kkct), 20 - 22 September 2018
- XXII. **AKUT MYELOİD LÖSEMİLİ BİR OLGUDA SİTOZİN ARABİNOZİD İLİŞKİLİ PULMONER TOKSİSİTE**
ÇİFTÇİLER R., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., AKSU S., DEMİROĞLU H., GÖKER H., ÖZCEBE O. İ., BÜYÜKAŞIK Y., SAYINALP N.

4.İLAÇ VE TEDAVİ KONGRESİ, Cyprus (Kktc), 19 - 23 September 2018, pp.254

- XXIII. **EFFECT OF THE INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS**
ALADAĞ KARAKULAK E., ÇİFTÇİLER R., DEMİROĞLU H., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.
The International Congress of BMT 2018, Busan, South Korea, 30 August - 01 September 2018
- XXIV. **Investigation of The Effect of Commercial Herbal Mixture on HepG2 Liver Cancer Cell Line by Proteomic Approach**
NENNİ M., ÖNCÜL S., ERCAN A., SÜSLÜ İ., ÇELEBİER M., HAZNEDAROĞLU İ. C.
12th International Symposium on Pharmaceutical Sciences, 26 - 29 June 2018
- XXV. **DOES ASYMPTOMATIC D-DIMER ELEVATION PREDICT THROMBOSIS IN PATIENTS ON IMMUNOMODULATORY DRUGS IN MULTIPLE MYELOMA: REAL-LIFE DATA**
AYDIN M. S., YAZGAN S. Ç., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., GÖKER H., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.
23rd Congress of EHA, Stockholm, Sweden, 14 - 17 June 2018
- XXVI. **Does Asymptomatic D-Dimer Elevation Predict Thrombosis in Patient on Immunomodulatory Drugs in Multiple Myeloma: Real-Life Data**
AYDIN M. S., YAZGAN S. C., ALADAĞ KARAKULAK E., ÇİFTÇİLER R., KELKİTLİ E., TURGUT M., GÖKER H., DEMİROĞLU H., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C., et al.
European Hematology Association, 14 - 17 June 2018
- XXVII. **PLAZMA HÜCRELİ LÖSEMİ ŞEKLİNDE PREZENTE OLAN WALDENSTROM MAKROGOBULİNEMİSİ**
ÇİFTÇİLER R., OKAY M., ALADAĞ KARAKULAK E., HEZİYEV T., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., DEMİROĞLU H., BÜYÜKAŞIK Y., GÖKER H., et al.
2. HEMATOLOJİK İMMUNOLOJİ KONGRESİ, Cyprus (Kktc), 4 - 06 May 2018
- XXVIII. **Common medical problems in adult patients with Hemophilia A: A single center experience**
AYDIN M. S., OKAY M., ÇİFTÇİLER R., ALADAĞ KARAKULAK E., DEMİROĞLU H., GÖKER H., BÜYÜKAŞIK Y., ÖZCEBE O. İ., SAYINALP N., HAZNEDAROĞLU İ. C., et al.
15. INTERNATIONAL HEMOPHILIA CONGRESS OF TURKEY, İstanbul, Turkey, 4 - 07 April 2018
- XXIX. **Echocardiographic Evaluation of Patients with Hodgkin and Non Hodgkin Lymphoma before and after Hematopoietic Stem Cell Transplantation**
KELKİTLİ E., BÜYÜKAŞIK Y., DEMİROĞLU H., ŞAHİNER M. L., OKAY M., AYDIN M. S., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C., TEKİN F., et al.
59th ASH, 9 - 12 December 2017, vol.130, pp.5521
- XXX. **Prognosis of Multiple Myeloma in Younger Patients Who Are Undergoing Upfront Autologous Stem Cell Transplantation**
KELKİTLİ E., GÖKER H., DEMİROĞLU H., TURGUT M., OKAY M., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., AYDIN M. S., tekin f., et al.
LYMPHOMA AND MYELOMA 2017, New York, United States Of America, 26 - 28 November 2017, vol.1, pp.43-44
- XXXI. **Donor Lymphocyte Infusions: Single Center Experience**
KELKİTLİ E., GÖKER H., TURGUT M., DEMİROĞLU H., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., OKAY M., AYDIN M. S., tekin f., et al.
LYMPHOMAMYELOMA 2017, New York, United States Of America, 26 - 28 November 2017, vol.1, pp.48
- XXXII. **The Modelled Effectiveness of Ruxolitinib on survival in PV Patients with Hydroxyurea Resistance /Intolerance in Turkey**
BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., ÖZET G., Ar C., Özcan M., Güvenç B., Yaşar N., Paralı E., Özkan B., Özdemir O.
ISPOR 20th Annual European Congress, 4 - 08 November 2017
- XXXIII. **Epidemiological Estimates and Treatment Practice Pattern in Polycythemia Vera Patients in Turkey: Results Based on an Expert Panel**
BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., ÖZET G., Ar C., Özcan M., Güvenç B., Yaşar N., Paralı E., Özkan B., Özdemir O.
ISPOR 20th Annual European Congress, 4 - 08 November 2017
- XXXIV. **kronik myeloproliferatif neoplazili hastalarda ruxolitinib etkinlik ve güvenliği: çok merkezli ve geriye dönük çalışma**

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., PİR A., karakuş v., özgür g., kiş c., ceran f., et al.

43.ulusal hematoloji kongresi, Turkey, 1 - 04 November 2017

XXXV. KRONİK MYELOPROLİFERATİF NEOPLAZİLİ HASTALARDA RUKSOLİTİNİB ETKİNLİK VE GÜVENLİĞİ: ÇOK MERKEZLİ VE GERİYE DÖNÜK ÇALIŞMA.

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ A. F., AYDOĞDU İ., PİR A., karakuş v., özgür g., Kiş c., ceran f., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017

XXXVI. Donor Lymphocyte Infusion: Single Center Experience

KELKİTLİ E., GÖKER H., TURGUT M., Demiroğlu H., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., OKAY M., Aydın S., Tekin F., et al.

LYMHOMA MYELOMA 2017, 26 - 28 October 2017

XXXVII. Prognosis of Multiple Myeloma in Younger Patients who Undergoing Upfront Autologous Stem Cell Transplantation

KELKİTLİ E., GÖKER H., demiroglu H., TURGUT M., SAYINALP N., AKSU S., HAZNEDAROĞLU İ. C., Aydın S., Tekin F., BÜYÜKAŞIK Y.

LYMPHOMA MYELOMA 2017, 26 - 28 October 2017

XXXVIII. Efficacy and safety of Ruxolitinib in Turkish Patients with chronic myeloproliferatif neoplasms:A multicenter and retrospective analysis

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., yilmaz f., AYDOĞDU İ., PİR A., Karakuş V., Özgür G., Kis C., Ceran F., et al.

AHOS, 21 - 24 September 2017

XXXIX. Efficacy and safety of ruxolitinib in Turkish patients with chronic myeloproliferative neoplasms:A multicenter and retropective analysis

SOYER N., TURGUT M., HAZNEDAROĞLU İ. C., YILMAZ F., AYDOĞDU İ., PİR A., KARAKUŞ V., ÖZGÜR G., KIŞ C., CERAN F., et al.

4th Aegean Hematology Oncology Symposium, 21 - 24 September 2017

XL. EFFECT OF INDUCTION THERAPY ON SURVIVAL IN MULTIPLE MYELOMA PATIENTS

DEMİROĞLU H., ALADAĞ KARAKULAK E., AKSU S., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., SAYINALP N., ÖZCEBE O. İ., GÖKER H.

INTERNATIONAL CONGRESS OF BMT 2018, Busan, South Korea, 30 August - 01 September 2018, vol.53

XLI. Amyloidosis Induced Abnormal coagulopathy associated with multible coagulation Factor Deficiencies.

malkan Ü. Y., DEMİROĞLU H., AKSU S., HAZNEDAROĞLU İ. C., SAYINALP N.

XXVI. Congress of the international society on Thrombosis and Haemostasis, Berlin, Germany, 08 July 2017 - 13 January 2018, vol.1, pp.402

XLII. The Impact of Chemo/Immune Therapy--Related Cytopenias on the Clinical Course of Chronic Lymphoid Leukemia

OKAY M., HAZNEDAROĞLU İ. C., malkan Ü. Y., GÜNEŞ G., aslan n., AKSU S., ÖZCEBE O. İ., BÜYÜKAŞIK Y., DEMİROĞLU H., SAYINALP N.

iwcll2017, New York, United States Of America, 12 - 15 May 2017

XLIII. Kemoterapiye refrakter primer mediastinal granülositik sarkom hastasının allojeneik kök hücre transplantasyonu ile tedavisi

ETGÜL S., MALKAN Ü. Y., TURGUT M., DEMİROĞLU H., BÜYÜKAŞIK Y., HAZNEDAROĞLU İ. C., GÖKER H.

2. Hematolojik Onkoloji Kongresi, Cyprus (Kktc), 16 - 19 February 2017

XLIV. Determination of chemoterapoetic drug sensitivity subgroups of acute leukemia

TÜRK S., Ghasemi M., MALKAN Ü. Y., Erikci A., GÖKER H., SAYINALP N., HAZNEDAROĞLU İ. C., Gure A. O., UÇAR G.

41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Turkey, 3 - 08 September 2016, vol.283, pp.373-374

XLV. Determination of chemoterapoetic drugsensitivity subgroups of acute leukemia

Türk S., Ghasemi M., malkan Ü. Y., ERİKÇİ A., GÖKER H., HAZNEDAROĞLU İ. C., GÜRE A. O., UÇAR G.

The FEBS Journal, 3 - 08 September 2016

- XLVI. AN IGD MYELOMA CASE THAT IS RESISTANT TO CARFILZOMIB**
Malkan Ü. Y., GÜNEŞ G., ETGÜL S., HAZNEDAROĞLU İ. C., DEMİROĞLU H., GÖKER H.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- XLVII. A COMPOSITE LYMPHOMA CASE**
Malkan Ü. Y., GÜNEŞ G., Yayar O., DEMİROĞLU H., GÖKER H., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- XLVIII. BLEOMYCIN-INDUCED INTERSTITIAL LUNG DISEASE: A CASE REPORT**
Malkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., HAZNEDAROĞLU İ. C., BÜYÜKAŞIK Y.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- XLIX. A CHRONIC MYELOID LEUKEMIA CASE WHO HAS DISCONTINUED IMATINIB TREATMENT**
Malkan Ü. Y., GÜNEŞ G., Aslan T., Yayar O., ÖZCEBE O. İ., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- L. AN ACUTE MYELOID LEUKEMIA PATIENT COMPLICATED WITH HYPERLEUKOCYTOSIS**
Malkan Ü. Y., GÜNEŞ G., Yayar O., HAZNEDAROĞLU İ. C., AKSU S., ÖZCEBE O. İ.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- LI. THERAPY-RELATED MYELODYSPLASTIC SYNDROME AFTER THE SUCCESSFUL TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA**
Malkan Ü. Y., GÜNEŞ G., Yayar O., AKSU S., DEMİROĞLU H., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- LII. A LATE-ONSET ACUTE GRAFT VERSUS HOST DISEASE CASE WHO IS RESISTANT TO BOTH TACROLIMUS AND CYCLOSPORINE**
Malkan Ü. Y., GÜNEŞ G., Aslan T., AKSU S., GÖKER H., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- LIII. A PLASMA CELL LEUKEMIA CASE**
Malkan Ü. Y., GÜNEŞ G., ETGÜL S., AKSU S., SAYINALP N., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- LIV. TREATMENT OF PYODERMA GANGRENOSUM WITH THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: A CASE REPORT**
Malkan Ü. Y., GÜNEŞ G., Yayar O., Aslan T., AKSU S., HAZNEDAROĞLU İ. C.
6th International Eurasian Hematology Congress, Antalya, Turkey, 14 - 18 October 2015, vol.39
- LV. Prognostic Factors for Survival of Elderly Patients with Acute Myeloid Leukemia after Intensive Chemotherapy: Validation of 3 Popular Prognostic Models**
Koca E., Halacoglu A., Malkan Ü. Y., Arica D., Karakus S., GÖKER H., HAZNEDAROĞLU İ. C., SAYINALP N., BÜYÜKAŞIK Y.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- LVI. Lower Doses of Plerixafor Use Is Sufficient to Effectively Mobilize PBSC (Peripheral Blood Hematopoietic Stem Cells) When Compared to Standard Administration**
GÖKER H., ELİAÇIK E., Altuntas F., Tekgunduz E., ÖZDEMİR E., Isik A., Kayikci O., Kaya A. H., AKSU S., HAZNEDAROĞLU İ. C., et al.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- LVII. Evaluation of Anti-Neoplastic Effects of a New Hemostatic Agent Ankaferd Blood Stopper on Myeloma Cell Line and Plasmocytoma Development in Balb/c Mice: Results of the First in Vitro and in Vivo Study**
Avcu F., Guner M., Misirci M., Elci P., Safali M., GÖKER H., HAZNEDAROĞLU İ. C.
56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124
- LVIII. GENERIC IMATINIB MESYLATE IS AS EFFECTIVE AS ORIGINAL GLIVEC IN THE MANAGEMENT OF CML**
AKSU S., AKTİMUR S., ARICA D., ATAY M. H., BEKTAŞ Ö., BÜYÜKAŞIK Y., DEMİROĞLU H., ELİAÇIK E., EŞME M., GÖKER

H., et al.

20th Congress of the European Hematology Association Vienna, Austria June 11-14,2015, 11 - 14 June 2014

LIX. Ultrastructural analyses of novel chimeric nanohemostat generated via peptide nanofibers and ABS hemostat at the renal tissue level

HURİ E., HAZNEDAROĞLU İ. C., FIRAT A., ERGUN K. M., HAYRAN H. M.

18th Congress EHA, Stockholm, Switzerland, 13 - 18 June 2013

LX. Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line

Baccarani M., Castagnetti F., Simonsson B., Porkka K., HAZNEDAROĞLU İ. C., Nagler A., Palandri F., Cambrin G. R., Levato L., Palmieri F., et al.

50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2008, vol.112, pp.75-76

LXI. Haemostatic actions of the folkloric medicinal plant extract, Ankaferd Blood Stopper

GÖKER H., HAZNEDAROĞLU İ. C., Ercetin S., Kirazli S., Akman U., Ozturk Y., Firat C. H.

49th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 8 - 11 December 2007, vol.110

LXII. Over-expression of the local bone marrow renin-angiotensin system in acute myeloid leukemia.

Beyazit Y., Aksu S., Haznedaroglu I., Kekilli M., Misirlioglu M., Tuncer S., Koca E., Cetiner D., Buyukasik Y., Sayinalp N., et al.

47th Annual Meeting of the American-Society-of-Hematology, Georgia, United States Of America, 10 - 13 December 2005, vol.106

LXIII. Levels of the circulating leukemia inhibitory factor in patients with vasculitis

Ozbalkan Z., Kiraz S., Ertenli I., Ozturk M., Haznedaroglu I., Ureten K., Onat A., Apras S., Akdogan A., Calguneri M.

Annual European Congress of Rheumatology, Lisbon, Portugal, 18 June 2003, vol.62, pp.447-448

LXIV. Thrombopoietin levels in the pulmonary vessels in patients with and without pulmonary hypertension.

Haznedaroglu I., Atalar E., Kocoglu M., Aksu S., Goker H., Buyukasik Y., Sayinalp N., Ozcebe O., Ozmen F., Dundar S., et al.

44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 December 2002, vol.100

LXV. Eozinofili ile Seyreden Anjiolenfoid Hiperplazi: Bir Olgu Sunumu

AKSOY B., HAZNEDAROĞLU İ. C., ŞAHİN S., Bükülmez G., GÖKÖZ Ö., Gököz A., KARADUMAN A.

IV. Çukurova Dermatoloji Günleri, Adana, Turkey, 30 May - 02 June 2002

Supported Projects

HAZNEDAROĞLU İ. C., TACAL Ö., ÇELEBİER M., SÜSLÜ İ., TÜBİTAK Project, 114S500 Ankaferd Bloodstopper Kanama Durdurucu nun Kolon Kanseri Üzerine İyileştirici Etkisinin Moleküler Düzeyde İncelenmesi, 2015 - Continues

SAYINALP N., AKBABA T. H., ALADAĞ KARAKULAK E., HAZNEDAROĞLU İ. C., İNKAYA A. Ç., PEYNİRCİOĞLU B., Project Supported by Higher Education Institutions, COVID-19 Hastalarında Anjiyotensin Dönüştürücü Enzim Gen

Polimorfizmlerinin Klinik Sonlanımlara Etkisinin Araştırılması, 2020 - 2021

TÜRK S., TÜRK C., UÇAR G., DEMİRKOL CANLI S., HAZNEDAROĞLU İ. C., Project Supported by Higher Education Institutions, Stafilkokkal enterotoksinler SEA ve SEB varlığında Akut miyeloid lösemi (AML) hücre hatlarının ilaç yanıtı profilinin ve kemoterapiye yanıtının belirlenmesi, 2019 - 2021

ÜNER A., ÖZOĞUL E., HAZNEDAROĞLU İ. C., GÜÇ D., OKAY M., Project Supported by Higher Education Institutions, Myeloproliferatif Neoplazilerde Görülebilecek Genetik Mutasyonların Araştırılması, 2018 - 2020

HAZNEDAROĞLU İ. C., Türk Türk S., GHASEMİ M., OKAY M., Project Supported by Higher Education Institutions, Anjiyotensin II Sitokininin AMLde Losartan İlacı için Prognostik Biyobelirteç Olarak Kullanılması, 2018 - 2018

HAZNEDAROĞLU İ. C., MALKAN Ü. Y., GHASEMİ M., Project Supported by Higher Education Institutions, Ankaferd

Hemostatın Malign Melanom Üzerine İn Vitro Etkileri, 2015 - 2015

Metrics

Publication: 331

Citation (WoS): 2778

Citation (Scopus): 924

H-Index (WoS): 29

H-Index (Scopus): 14